<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6963298</article-id><article-id pub-id-type="doi">10.3390/vaccines7040179</article-id><article-id pub-id-type="publisher-id">vaccines-07-00179</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Disease Resurgence, Production Capability Issues and Safety Concerns in the Context of an Aging Population: Is There a Need for a New Yellow Fever Vaccine?</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7741-7072</contrib-id><name><surname>Tomashek</surname><given-names>Kay M.</given-names></name><xref rid="c1-vaccines-07-00179" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Challberg</surname><given-names>Mark</given-names></name></contrib><contrib contrib-type="author"><name><surname>Nayak</surname><given-names>Seema U.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Schiltz</surname><given-names>Helen F.</given-names></name></contrib></contrib-group><aff id="af1-vaccines-07-00179">Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Bethesda, MD 20892-9826, USA; <email>MCHALLBERG@niaid.nih.gov</email> (M.C.); </aff><author-notes><corresp id="c1-vaccines-07-00179"><label>*</label>Correspondence: <email>kay.tomashek@nih.gov</email>; Tel.: 240-383-0540</corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>11</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2019</year></pub-date><volume>7</volume><issue>4</issue><elocation-id>179</elocation-id><history><date date-type="received"><day>10</day><month>10</month><year>2019</year></date><date date-type="accepted"><day>05</day><month>11</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 by the authors.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Yellow fever is a potentially fatal, mosquito-borne viral disease that appears to be experiencing a resurgence in endemic areas in Africa and South America and spreading to non-endemic areas despite an effective vaccine. This trend has increased the level of concern about the disease and the potential for importation to areas in Asia with ecological conditions that can sustain yellow fever virus transmission. In this article, we provide a broad overview of yellow fever burden of disease, natural history, treatment, vaccine, prevention and control initiatives, and vaccine and therapeutic agent development efforts.</p></abstract><kwd-group><kwd>yellow fever</kwd><kwd>vaccine</kwd><kwd>flavivirus</kwd><kwd>mosquito-borne</kwd><kwd>acute febrile illness</kwd></kwd-group></article-meta></front><body><sec id="sec1-vaccines-07-00179"><title>1. Background </title><p>Yellow fever (YF) is a potentially fatal disease caused by a member of the family Flaviviridae, genus <italic>Flavivirus</italic>, yellow fever virus (YFV) [<xref rid="B1-vaccines-07-00179" ref-type="bibr">1</xref>]. The disease is endemic in equatorial Africa, tropical areas of South America, eastern Panama and Trinidad. YFV is transmitted to humans and non-human primates (NHP) by <italic>Aedes</italic> spp. mosquitoes in Africa [<xref rid="B2-vaccines-07-00179" ref-type="bibr">2</xref>,<xref rid="B3-vaccines-07-00179" ref-type="bibr">3</xref>] and <italic>Aedes</italic> spp., <italic>Haemagogus</italic> spp. and <italic>Sabethes</italic> spp. mosquitoes in South America [<xref rid="B4-vaccines-07-00179" ref-type="bibr">4</xref>,<xref rid="B5-vaccines-07-00179" ref-type="bibr">5</xref>]. There are three transmission cycles for YFV: a sylvatic cycle involving NHP and <italic>Aedes africanus, Haemagogus</italic> spp. or <italic>Sabethes</italic> spp. mosquitoes in jungles with sporadic transmission to humans frequenting these areas; an intermediate cycle involving NHPs, humans and <italic>Aedes</italic> spp. mosquitoes in African savannah settings; and an urban cycle involving primarily <italic>Aedes aegypti</italic> mosquitoes and humans in cities. While the sylvatic and intermediate YFV transmission cycles account for most human disease, in the last decade there has been a resurgence in urban outbreaks [<xref rid="B6-vaccines-07-00179" ref-type="bibr">6</xref>]. Many of the recent African outbreaks, including in Uganda in 2010 [<xref rid="B7-vaccines-07-00179" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-07-00179" ref-type="bibr">8</xref>], Ethiopia in 2013 [<xref rid="B9-vaccines-07-00179" ref-type="bibr">9</xref>], Angola in 2015 [<xref rid="B10-vaccines-07-00179" ref-type="bibr">10</xref>,<xref rid="B11-vaccines-07-00179" ref-type="bibr">11</xref>] and Nigeria in 2017 [<xref rid="B12-vaccines-07-00179" ref-type="bibr">12</xref>], were the first YF outbreaks in these countries in more than 10 years. Moreover, the Angola outbreak resulted in spread to the Democratic Republic of the Congo (DRC)[<xref rid="B13-vaccines-07-00179" ref-type="bibr">13</xref>], Mauritania and Kenya [<xref rid="B14-vaccines-07-00179" ref-type="bibr">14</xref>], as well as importation of disease into China by unvaccinated Chinese nationals who were infected while working in Angola [<xref rid="B15-vaccines-07-00179" ref-type="bibr">15</xref>,<xref rid="B16-vaccines-07-00179" ref-type="bibr">16</xref>]. In South America, a large urban outbreak was detected in 2016 in a non-endemic area of Brazil, and from 2016 to March of 2019 there were 2204 reported human cases or more cases than in the previous 20 years combined [<xref rid="B17-vaccines-07-00179" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-07-00179" ref-type="bibr">18</xref>,<xref rid="B19-vaccines-07-00179" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-07-00179" ref-type="bibr">20</xref>,<xref rid="B21-vaccines-07-00179" ref-type="bibr">21</xref>,<xref rid="B22-vaccines-07-00179" ref-type="bibr">22</xref>]. </p><p>Collectively, these recent YF outbreaks have increased the level of concern about the disease and its potential to spread to non-endemic areas in Africa and Latin America and countries in Asia where YFV is absent [<xref rid="B23-vaccines-07-00179" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-07-00179" ref-type="bibr">24</xref>]. Factors that may favor the spread of the disease and increase the likelihood of large urban outbreaks include more abundant vector populations over a wider geographic area [<xref rid="B25-vaccines-07-00179" ref-type="bibr">25</xref>], increasing urbanization, a highly mobile human population [<xref rid="B21-vaccines-07-00179" ref-type="bibr">21</xref>,<xref rid="B26-vaccines-07-00179" ref-type="bibr">26</xref>,<xref rid="B27-vaccines-07-00179" ref-type="bibr">27</xref>,<xref rid="B28-vaccines-07-00179" ref-type="bibr">28</xref>], an increase in the NHP population [<xref rid="B29-vaccines-07-00179" ref-type="bibr">29</xref>], and NHP displacement due to deforestation in the Amazon Basin and forested areas in equatorial Africa [<xref rid="B24-vaccines-07-00179" ref-type="bibr">24</xref>,<xref rid="B30-vaccines-07-00179" ref-type="bibr">30</xref>]. Low population immunity to YFV in neighboring endemic areas due to under vaccination may also be a contributing factor [<xref rid="B31-vaccines-07-00179" ref-type="bibr">31</xref>,<xref rid="B32-vaccines-07-00179" ref-type="bibr">32</xref>]. </p><p>In response to outbreaks in Angola and DRC, in 2017, the World Health Organization (WHO), UNICEF, and Gavi, the Vaccine Alliance developed a new global initiative, the Eliminate Yellow Fever Epidemics (EYE) Strategy, in collaboration with 50 partners in support of 40 high-risk countries [<xref rid="B33-vaccines-07-00179" ref-type="bibr">33</xref>]. EYE focuses on preventing sporadic YF cases from developing into outbreaks, mitigating outbreaks, and preventing exportation once outbreaks are identified. The goal of EYE is to eliminate YF outbreaks globally by 2026 by vaccinating 1.4 billion people in 40 countries by supporting vaccination programs and campaigns and strengthening surveillance and laboratory capacity to detect, monitor and respond to YFV transmission. EYE built upon lessons learned from the WHO Yellow Fever Initiative which was created in collaboration with Gavi, the Vaccine Alliance and UNICEF in response to YF outbreaks in West Africa in the early 2000s. The Yellow Fever Initiative introduced YF vaccine into routine childhood immunization schedules in endemic countries, conducted mass preventive campaigns in risk areas, and established a global vaccine stockpile to respond to outbreaks. While initiative efforts successfully prevented YF outbreaks in West Africa, many of the recent African outbreaks have occurred in Central and East Africa.</p></sec><sec id="sec2-vaccines-07-00179"><title>2. Burden of Disease </title><p>More than 900 million people reside in 35 African and 13 Central and South American countries where there is high to moderate risk of YFV transmission [<xref rid="B33-vaccines-07-00179" ref-type="bibr">33</xref>]. While the last estimate of YF incidence and mortality is from 1992 [<xref rid="B34-vaccines-07-00179" ref-type="bibr">34</xref>], 90% of YF cases reported to WHO via passive surveillance are still from Africa. One recent study estimated that there were 130,000 (95% CI 51,000&#x02013;380,000) YF cases with fever and jaundice or hemorrhage in 2013, including 78,000 (95% CI 19,000&#x02013;180,000) deaths in Africa [<xref rid="B35-vaccines-07-00179" ref-type="bibr">35</xref>]. In endemic areas of Africa, natural immunity accumulates with age, thereby putting infants and children at highest risk. In the Americas, the annual reported incidence of YF is typically less than 500 cases with the exception of 524 cases in 1995, 825 cases in 2017, and 1401 cases in 2018 [<xref rid="B4-vaccines-07-00179" ref-type="bibr">4</xref>,<xref rid="B36-vaccines-07-00179" ref-type="bibr">36</xref>]. Traditionally, most cases in the Americas were reported among unimmunized men thought to be exposed to YFV-infected mosquitoes while working in forested areas.</p><p>After being bitten by a YFV-infected mosquito, the incubation period is 2 to 9 days [<xref rid="B37-vaccines-07-00179" ref-type="bibr">37</xref>]. Most infected people develop subclinical infections or mild, self-limited clinically-apparent infections not requiring medical attention [<xref rid="B38-vaccines-07-00179" ref-type="bibr">38</xref>]. Classic YF has three stages. The first stage occurs while the patient is viremic and consists of nonspecific clinical features including fever, chills, generalized malaise, headache, red conjunctivae, photophobia, low back pain, myalgia, anorexia, nausea, vomiting, hepatomegaly, and epigastric and hepatic tenderness upon palpation. During this stage, patients are often leukopenic and have elevated serum transaminase levels, which may be predictive of ultimate disease severity [<xref rid="B39-vaccines-07-00179" ref-type="bibr">39</xref>,<xref rid="B40-vaccines-07-00179" ref-type="bibr">40</xref>,<xref rid="B41-vaccines-07-00179" ref-type="bibr">41</xref>]. After 3 to 4 days, patients enter a second 24 to 48-hour remission stage when they become afebrile and their symptoms lessen. Most patients remain afebrile and recover while about 12% (95% CI 5&#x02013;26) develop severe disease and enter the third stage of illness [<xref rid="B38-vaccines-07-00179" ref-type="bibr">38</xref>]. During the third stage, the fever returns, and patients develop nausea, vomiting, epigastric pain, jaundice, oliguria, and hemorrhagic manifestations. Patients may develop metabolic acidosis and organ impairment involving the liver, pancreas, kidneys and cardiovascular system [<xref rid="B42-vaccines-07-00179" ref-type="bibr">42</xref>]. Neurologic complications may occur including seizures, encephalopathy, cerebral edema, and coma. The case fatality rate among patients with severe disease has been estimated to be 47% (95% CI 31&#x02013;62)[<xref rid="B38-vaccines-07-00179" ref-type="bibr">38</xref>].</p></sec><sec id="sec3-vaccines-07-00179"><title>3. Immune Response after Natural Infection</title><p>Those who recover from YF likely have long-lasting immunity, however most data on immune response and antibody kinetics in YF are from vaccine models [<xref rid="B43-vaccines-07-00179" ref-type="bibr">43</xref>]. IgM antibodies are typically detected during the first week of illness, peak during the second week, and rapidly decline over the next sixty days. While IgM antibodies can persist after YF immunization, it is unknown if there is similar endurance after natural infection [<xref rid="B44-vaccines-07-00179" ref-type="bibr">44</xref>]. Neutralizing antibodies, which primarily consist of IgG antibodies, can remain for many years after immunization and natural infection, and can confer protection against re-infection [<xref rid="B45-vaccines-07-00179" ref-type="bibr">45</xref>,<xref rid="B46-vaccines-07-00179" ref-type="bibr">46</xref>,<xref rid="B47-vaccines-07-00179" ref-type="bibr">47</xref>,<xref rid="B48-vaccines-07-00179" ref-type="bibr">48</xref>]. There are no documented cases of repeated YFV infection, even in several historical cohorts [<xref rid="B49-vaccines-07-00179" ref-type="bibr">49</xref>]. Evidence also suggests that previous heterologous flavivirus exposure, for example from prior dengue virus infection, may provide partial cross protection against severe YF [<xref rid="B43-vaccines-07-00179" ref-type="bibr">43</xref>,<xref rid="B50-vaccines-07-00179" ref-type="bibr">50</xref>,<xref rid="B51-vaccines-07-00179" ref-type="bibr">51</xref>].</p></sec><sec id="sec4-vaccines-07-00179"><title>4. Treatment for Yellow Fever</title><p>The standard treatment for YF patients is supportive care, as there are currently no FDA-approved therapeutic agents to treat the disease or prevent disease progression despite decades of research and development investments [<xref rid="B52-vaccines-07-00179" ref-type="bibr">52</xref>]. Supportive care may include nutritional support, administration of intravenous fluids, and acetaminophen for pain and fever. Patients with severe disease require intensive care management to prevent and treat shock, metabolic acidosis, hypoglycemia, stress-induced gastritis, bleeding, hepatic dysfunction, renal failure, and secondary bacterial infections [<xref rid="B53-vaccines-07-00179" ref-type="bibr">53</xref>]. Patients should be protected from mosquito bites for five days after fever onset to avoid infecting mosquitoes.</p><p>Currently, the most promising therapeutic agents in early clinical development are nucleoside analogs that inhibit viral RNA-dependent RNA polymerases [<xref rid="B54-vaccines-07-00179" ref-type="bibr">54</xref>,<xref rid="B55-vaccines-07-00179" ref-type="bibr">55</xref>,<xref rid="B56-vaccines-07-00179" ref-type="bibr">56</xref>,<xref rid="B57-vaccines-07-00179" ref-type="bibr">57</xref>,<xref rid="B58-vaccines-07-00179" ref-type="bibr">58</xref>]. For example, galidesivir has in vitro and in vivo activity against a broad range of RNA viruses, including Ebola, Marburg and YFV [<xref rid="B58-vaccines-07-00179" ref-type="bibr">58</xref>,<xref rid="B59-vaccines-07-00179" ref-type="bibr">59</xref>]. A Phase 1 clinical trial to evaluate the safety, pharmacokinetics and anti-viral effects of galidesivir in patients with laboratory-confirmed YF is ongoing [<xref rid="B60-vaccines-07-00179" ref-type="bibr">60</xref>]. Numerous studies have identified other potential antiviral candidates; however, none have entered clinical trials. For example, sofosbuvir, a uridine analog used to treat hepatitis C, has shown antiviral activity against YFV in cell-based assays and rodent infection models [<xref rid="B54-vaccines-07-00179" ref-type="bibr">54</xref>,<xref rid="B57-vaccines-07-00179" ref-type="bibr">57</xref>]. Further preclinical development needs to be done for this and other candidates, and their clinical utility to treat YF remains untested.</p><p>A few monoclonal antibodies targeting the conformationally conserved envelop (E) protein Domain II or III involved in membrane fusion have shown promise with many demonstrating broad cross-activity against multiple flaviviruses including YFV [<xref rid="B61-vaccines-07-00179" ref-type="bibr">61</xref>,<xref rid="B62-vaccines-07-00179" ref-type="bibr">62</xref>,<xref rid="B63-vaccines-07-00179" ref-type="bibr">63</xref>,<xref rid="B64-vaccines-07-00179" ref-type="bibr">64</xref>,<xref rid="B65-vaccines-07-00179" ref-type="bibr">65</xref>,<xref rid="B66-vaccines-07-00179" ref-type="bibr">66</xref>]. One example of a promising, first-in-class monoclonal antibody for YF is TY014 developed by Tychan, Singapore [<xref rid="B67-vaccines-07-00179" ref-type="bibr">67</xref>]. TY014 was designed to neutralize multiple strains of YFV by binding to an epitope on the E protein on the surface of the virus, thereby preventing viral fusion to the host cell during viral entry [<xref rid="B68-vaccines-07-00179" ref-type="bibr">68</xref>]. TY014 will be evaluated in a Phase I clinical trial in healthy adult subjects to assess safety and the effect of TY014 on vaccine-associated viremia [<xref rid="B67-vaccines-07-00179" ref-type="bibr">67</xref>].</p></sec><sec id="sec5-vaccines-07-00179"><title>5. Disease Prevention</title><p>People living in or traveling to areas with risk for YFV transmission should avoid mosquito bites whenever possible [<xref rid="B69-vaccines-07-00179" ref-type="bibr">69</xref>]. Those who get YF should avoid mosquito bites for five days after fever onset to avoid infecting naive mosquitoes that can then transmit YFV to others. Persons &#x02265;9 months old living in or traveling to areas with risk for YFV transmission should be vaccinated unless they have a contraindication to vaccination with a live-attenuated vaccine.</p><p>Preventing YF outbreaks is challenging for public health authorities for several reasons. First, public health officials have no control over the largely inaccessible sylvatic mosquito species that lay eggs in tree holes and the NHP reservoir [<xref rid="B24-vaccines-07-00179" ref-type="bibr">24</xref>]. Instead, epizootics among NHPs are monitored as sentinel events to enable early detection of human cases [<xref rid="B70-vaccines-07-00179" ref-type="bibr">70</xref>,<xref rid="B71-vaccines-07-00179" ref-type="bibr">71</xref>]. Second, <italic>Aedes spp.</italic> mosquitoes have become more abundant and geographically dispersed in recent decades, in part due to ineffective and unsustainable vector control strategies [<xref rid="B72-vaccines-07-00179" ref-type="bibr">72</xref>,<xref rid="B73-vaccines-07-00179" ref-type="bibr">73</xref>]. Despite limited evidence supporting the effectiveness of control strategies, novel mosquito modification methods combined with an updated integrated vector control program may be the most effective option to mitigate YFV transmission in urban areas [<xref rid="B74-vaccines-07-00179" ref-type="bibr">74</xref>,<xref rid="B75-vaccines-07-00179" ref-type="bibr">75</xref>]. Third, the disease is largely sub-clinical, so outbreaks may go undetected until severe cases are identified by surveillance. This allows the outbreak to become widespread before interventions, like mass vaccination campaigns, are initiated. Last, while the current YF 17D vaccine is thought to be effective [<xref rid="B76-vaccines-07-00179" ref-type="bibr">76</xref>], 80% of the population needs to be vaccinated in areas with risk for YFV transmission to prevent outbreaks. This level of coverage requires significant support and commitment to national vaccination programs and control strategies as well as the capacity to predict where YF outbreaks may occur and adapt strategies to expand coverage to emerging at-risk areas [<xref rid="B77-vaccines-07-00179" ref-type="bibr">77</xref>,<xref rid="B78-vaccines-07-00179" ref-type="bibr">78</xref>,<xref rid="B79-vaccines-07-00179" ref-type="bibr">79</xref>,<xref rid="B80-vaccines-07-00179" ref-type="bibr">80</xref>,<xref rid="B81-vaccines-07-00179" ref-type="bibr">81</xref>].</p></sec><sec id="sec6-vaccines-07-00179"><title>6. Yellow Fever Vaccines and Production Capacity</title><p>A live-attenuated YF vaccine was first developed in 1936 using an attenuated wild-type YFV strain that was isolated in 1927 from a Ghanaian patient named Mr. Asibi [<xref rid="B82-vaccines-07-00179" ref-type="bibr">82</xref>,<xref rid="B83-vaccines-07-00179" ref-type="bibr">83</xref>]. The Asibi 17D strain was passaged 53 times in monkeys, followed by serial passage in minced tissue preparations: mouse embryo (18 passages), whole chick embryo (58 passages), and whole chick embryo without brain and spinal cord (100 passages) [<xref rid="B84-vaccines-07-00179" ref-type="bibr">84</xref>]. During the passage series, the virus was assayed for neurotropism in mice by intracerebral injection, and pathogenicity in monkeys by intracerebral and extraneural administration. The 176th viral passage was selected to make vaccine sub-strains 17D-204 and 17DD because it was less lethal when delivered intracerebrally than a 114th passage strain, the first strain to lose pathogenicity in mice. A third sub-strain, which is a derivative of 17D-204, the 17D-213 sub-strain, was produced in 1977 and is a reference stock maintained by WHO for new manufacturers or emergency production [<xref rid="B43-vaccines-07-00179" ref-type="bibr">43</xref>,<xref rid="B85-vaccines-07-00179" ref-type="bibr">85</xref>].</p><p>Currently, six YF 17D vaccines are produced worldwide, all of which are derived from the Asibi strain. Four are WHO-prequalified YF vaccines which are used internationally for WHO/UNICEF vaccination campaigns: Bio-Manguinhos/FIOCRUZ (Brazil), YF 17-DD vaccine; Sanofi Pasteur (France), YF 17D-204 vaccine, Stamaril&#x000ae;; Institut Pasteur Dakar (Senegal), YF 17D-204 vaccine; and the Chumakov Federal Scientific Center (Russian Federation), YF 17D-204 vaccine. In addition, the Sanofi Pasteur (USA), YF 17D-204 vaccine, YF-Vax&#x000ae; is used in the U.S. and Canada, and China has a YF 17D-204 vaccine produced for domestic use by the China National Biotech Group. </p><p>Even though there are several YF vaccine producers, two with large scale capability, supply has not been able to keep up with demand. Production capacity is limited because the vaccines are produced in embryonated eggs using a labor-intensive method that is relatively unchanged since 1945 [<xref rid="B85-vaccines-07-00179" ref-type="bibr">85</xref>]. As a result, only about 80 million doses are produced each year [<xref rid="B86-vaccines-07-00179" ref-type="bibr">86</xref>]. It is estimated that there are between 393.7 and 472.9 million people residing in YFV transmission risk areas who need to be vaccinated to achieve the recommended 80% population coverage threshold [<xref rid="B33-vaccines-07-00179" ref-type="bibr">33</xref>,<xref rid="B87-vaccines-07-00179" ref-type="bibr">87</xref>]. Moreover, the incidence of YF appears to be increasing not only in under-vaccinated areas but also in historically non-endemic areas [<xref rid="B6-vaccines-07-00179" ref-type="bibr">6</xref>]. When YF outbreaks occur, the vaccine supply is insufficient to meet the needs for mass vaccination campaigns [<xref rid="B88-vaccines-07-00179" ref-type="bibr">88</xref>]. For example, in an outbreak in Kinshasa in 2016, vaccine shortage led to the emergency use of a fractional (i.e., one-fifth) dose of YF 17-DD vaccine after the vaccine stockpile was depleted [<xref rid="B89-vaccines-07-00179" ref-type="bibr">89</xref>,<xref rid="B90-vaccines-07-00179" ref-type="bibr">90</xref>,<xref rid="B91-vaccines-07-00179" ref-type="bibr">91</xref>]. In 2018, a campaign using fractional doses of YF vaccine was initiated in Brazil in response to urban outbreaks in S&#x000e3;o Paulo and Rio de Janeiro. While fractional dosing may be employed during public health emergencies, broader application is not recommended because of insufficient data regarding the immunogenicity of fractional doses in infants, young children and human immunodeficiency virus (HIV)-infected persons living in endemic areas [<xref rid="B32-vaccines-07-00179" ref-type="bibr">32</xref>,<xref rid="B92-vaccines-07-00179" ref-type="bibr">92</xref>,<xref rid="B93-vaccines-07-00179" ref-type="bibr">93</xref>].</p></sec><sec id="sec7-vaccines-07-00179"><title>7. Safety Profile of Yellow Fever Vaccines </title><p>Serious adverse events (SAE) including deaths occur following administration of YF vaccine [<xref rid="B27-vaccines-07-00179" ref-type="bibr">27</xref>,<xref rid="B94-vaccines-07-00179" ref-type="bibr">94</xref>,<xref rid="B95-vaccines-07-00179" ref-type="bibr">95</xref>,<xref rid="B96-vaccines-07-00179" ref-type="bibr">96</xref>], and the frequency of vaccine-related SAEs for YF vaccine is comparable to the rate of vaccine-associated paralytic poliomyelitis with oral polio vaccine [<xref rid="B97-vaccines-07-00179" ref-type="bibr">97</xref>,<xref rid="B98-vaccines-07-00179" ref-type="bibr">98</xref>]. In addition, because YF vaccine is a live-attenuated vaccine produced in eggs, there are several contraindications and precautions to its administration [<xref rid="B99-vaccines-07-00179" ref-type="bibr">99</xref>]. Experts have called for the development of a safer YF vaccine ever since viscerotropic disease, an acute illness resembling severe wild-type disease but with higher lethality, was identified [<xref rid="B96-vaccines-07-00179" ref-type="bibr">96</xref>,<xref rid="B97-vaccines-07-00179" ref-type="bibr">97</xref>]. However, until we have a safer vaccine, healthcare providers and public health officials will have to determine if the benefit outweighs the risk among travelers to endemic areas and for populations living in non-endemic areas bordering endemic areas. </p><p>A review of U.S. Vaccine Adverse Event Reporting System (VAERS) data from 2007&#x02013;2013 found 3.8 SAEs per 100,000 vaccine doses [<xref rid="B94-vaccines-07-00179" ref-type="bibr">94</xref>], while a review of passive surveillance data from several non-endemic countries found rates ranging from 1.3 to 5.1 SAE per 100,000 vaccine doses [<xref rid="B98-vaccines-07-00179" ref-type="bibr">98</xref>]. The rate is known to increase with age such that 60&#x02013;69-year old vaccine recipients had a rate of 6.5 SAEs per 100,000 doses while those over 70 years old had a rate of 10.3 [<xref rid="B94-vaccines-07-00179" ref-type="bibr">94</xref>]. The three primary SAEs include anaphylaxis (0.2&#x02013;1.8 per 100,000 doses), neurologic disease (0.1&#x02013;3.9 per 100,000 doses) and viscerotropic disease (0.07&#x02013;0.4 per 100,000 doses) due to 17D virus infection of the liver and visceral organs [<xref rid="B98-vaccines-07-00179" ref-type="bibr">98</xref>,<xref rid="B100-vaccines-07-00179" ref-type="bibr">100</xref>].</p><p>Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) was first described in 2001, although cases as far back as the 1970s have been identified retrospectively [<xref rid="B43-vaccines-07-00179" ref-type="bibr">43</xref>]. While YEL-AVDs are rare events, the case fatality rate is &#x0003e;60%. YEL-AVD typically presents about 4 days after the first YF vaccine dose is administered and has a natural history similar to severe wild-type disease. YEL-AVD occurrence is thought to be due to underlying host susceptibility rather than the vaccine virus reverting to a virulent phenotype [<xref rid="B101-vaccines-07-00179" ref-type="bibr">101</xref>]. Risk factors for YEL-AVD include thymus disorders, thymectomy, autoimmune diseases (e.g., systemic lupus erythematosus), host genetics, and advanced age; vaccine recipients &#x02265;60 years have an incidence of 1.2 per 100,000 doses [<xref rid="B100-vaccines-07-00179" ref-type="bibr">100</xref>,<xref rid="B102-vaccines-07-00179" ref-type="bibr">102</xref>,<xref rid="B103-vaccines-07-00179" ref-type="bibr">103</xref>,<xref rid="B104-vaccines-07-00179" ref-type="bibr">104</xref>]. Older individuals may be at increased risk due to immune senescence and/or underlying chronic diseases. In fact, one study found that older first-time 17D vaccine recipients had a delayed antibody response and a longer duration of viremia than younger vaccine recipients [<xref rid="B105-vaccines-07-00179" ref-type="bibr">105</xref>]. Findings from animal models of YF disease support the hypothesis that an impaired innate immune system may allow dissemination of the 17D strain [<xref rid="B106-vaccines-07-00179" ref-type="bibr">106</xref>,<xref rid="B107-vaccines-07-00179" ref-type="bibr">107</xref>].</p><p>YFV is a neurotropic virus and while YF vaccine is attenuated, it is a live vaccine that replicates in the host and produces a brief viremia that has potential for neuroinvasion in a susceptible host. In addition, a recent study demonstrated that Schwann cells can support sustained replication of the 17D strain [<xref rid="B108-vaccines-07-00179" ref-type="bibr">108</xref>]. Encephalitis and meningoencephalitis associated with 17D vaccine administration in infants was first recognized in 1952 and led to the contraindication against vaccination of infants &#x0003c;6 months old [<xref rid="B109-vaccines-07-00179" ref-type="bibr">109</xref>]. Since then, vaccine-associated neurotropic disease (YEL-AND) has come to include not only neurologic disease due to direct viral invasion of the central nervous system (e.g., encephalitis and meningitis) but also autoimmune-mediated demyelination and neuropathy including Guillain-Barre&#x000b4; syndrome, acute disseminated encephalomyelitis, myelitis, and cranial neuropathies. YEL-AND typically occurs 2-56 days after the first YF vaccine dose is administered, and the disease is generally not fatal. YEL-AND tends to affect young infants, immunocompromised individuals, and the elderly. The incidence of YEL-AND is 2.2 cases per 100,000 vaccine doses among vaccine recipients &#x02265;60 years old [<xref rid="B110-vaccines-07-00179" ref-type="bibr">110</xref>,<xref rid="B111-vaccines-07-00179" ref-type="bibr">111</xref>,<xref rid="B112-vaccines-07-00179" ref-type="bibr">112</xref>]. In 2009, the first case of encephalitis in an infant was confirmed to be caused by YF vaccine virus transmitted via breastmilk [<xref rid="B113-vaccines-07-00179" ref-type="bibr">113</xref>,<xref rid="B114-vaccines-07-00179" ref-type="bibr">114</xref>,<xref rid="B115-vaccines-07-00179" ref-type="bibr">115</xref>]. As a result, breastfeeding women should not receive YF vaccine except when exposure to YFV cannot be avoided or travel cannot be postponed to YF endemic or epidemic areas.</p></sec><sec id="sec8-vaccines-07-00179"><title>8. Yellow Fever Vaccine Effectiveness</title><p>While there were no randomized, placebo-controlled clinical trials done to evaluate the efficacy or effectiveness of YF 17D vaccine prior to its use in humans, pre-clinical studies found that vaccination protected NHPs against a lethal challenge of YFV [<xref rid="B43-vaccines-07-00179" ref-type="bibr">43</xref>]. There is no evidence that vaccine effectiveness has played a role in the recent outbreaks as there is still only a single YFV serotype and while the lineages between South America and Africa continue to diverge, they are still very closely related [<xref rid="B116-vaccines-07-00179" ref-type="bibr">116</xref>]. Moreover, the majority (&#x0003e;90%) of vaccinated people develop neutralizing antibodies by 28 days after vaccination, and vaccine failures are thought to be rare [<xref rid="B117-vaccines-07-00179" ref-type="bibr">117</xref>]. A recent paper described 23 vaccine failures identified after &#x0003e;540 million doses of YF vaccine were administered, and five of these cases occurred before protective antibodies titers would be expected to develop after vaccination [<xref rid="B76-vaccines-07-00179" ref-type="bibr">76</xref>]. Observations and reports from the field support its effectiveness including the prevention of laboratory-acquired YFV infections among vaccinated staff and the decline in YF incidence after vaccination campaigns with subsequent cases identified only among unvaccinated individuals [<xref rid="B43-vaccines-07-00179" ref-type="bibr">43</xref>].</p><p>Not only is it considered an effective vaccine, but data suggests that a single dose of YF vaccine may confer life-long protection against YF disease [<xref rid="B117-vaccines-07-00179" ref-type="bibr">117</xref>,<xref rid="B118-vaccines-07-00179" ref-type="bibr">118</xref>]. In 2013, the WHO Strategic Advisory Group of Experts (SAGE) working group for YF vaccination recommended that the 2003 WHO position on 17D booster schedules and international health regulations be revised to remove the 10-year booster dose requirement [<xref rid="B118-vaccines-07-00179" ref-type="bibr">118</xref>]. In 2015, the Advisory Committee on Immunization Practices (ACIP) issued similar guidance on the adequacy of a single dose of YF vaccine for most travelers. However, ACIP also recommended that at-risk laboratory personnel and certain travelers receive additional doses of YF vaccine [<xref rid="B76-vaccines-07-00179" ref-type="bibr">76</xref>]. Additionally, the impact of no booster vaccination is being investigated among children as there is little evidence to support long-term persistence of protective immunity in primary vaccinated children [<xref rid="B119-vaccines-07-00179" ref-type="bibr">119</xref>].</p></sec><sec id="sec9-vaccines-07-00179"><title>9. Yellow Fever Vaccine Candidates</title><p>New YF vaccines that are produced using modern technologies are needed to address the limited production capacity of existing vaccines especially considering the expanding geographic distribution, threat of re-urbanization and possibility of introduction into YFV-na&#x000ef;ve Asia [<xref rid="B120-vaccines-07-00179" ref-type="bibr">120</xref>]. In addition, new YF vaccines would ideally have a better safety profile for infants, breastfeeding women, immunocompromised individuals, and older people [<xref rid="B98-vaccines-07-00179" ref-type="bibr">98</xref>]. While vaccines are being developed, dose-sparing methods are being investigated [<xref rid="B121-vaccines-07-00179" ref-type="bibr">121</xref>,<xref rid="B122-vaccines-07-00179" ref-type="bibr">122</xref>]. One method, intradermal administration of YF vaccine, mimics the natural route of transmission and takes advantage of the skin dendritic cells role in the immune response [<xref rid="B123-vaccines-07-00179" ref-type="bibr">123</xref>,<xref rid="B124-vaccines-07-00179" ref-type="bibr">124</xref>]. In one study, the immunogenicity of a fractional (one-fifth) intradermal dose of YF 17D vaccine was not inferior to that of a full subcutaneous dose.</p><p>One approach being taken to address these issues is to produce an inactivated whole virus vaccine using the 17D virus produced in cell culture [<xref rid="B120-vaccines-07-00179" ref-type="bibr">120</xref>,<xref rid="B125-vaccines-07-00179" ref-type="bibr">125</xref>,<xref rid="B126-vaccines-07-00179" ref-type="bibr">126</xref>,<xref rid="B127-vaccines-07-00179" ref-type="bibr">127</xref>,<xref rid="B128-vaccines-07-00179" ref-type="bibr">128</xref>,<xref rid="B129-vaccines-07-00179" ref-type="bibr">129</xref>]. Such a vaccine would provide scalable production and would likely not have the adverse effects associated with viral replication. A candidate vaccine comprised of 17D virus inactivated by treatment with beta-propiolactone (BPL) was shown to protect mice against a lethal YFV challenge [<xref rid="B129-vaccines-07-00179" ref-type="bibr">129</xref>]. In a Phase 1 clinical trial, two doses of this vaccine elicited neutralizing antibody titers that were like those obtained with live-attenuated 17D vaccine, although the durability of this immune response is not yet known [<xref rid="B130-vaccines-07-00179" ref-type="bibr">130</xref>]. Another similar inactivated whole virus vaccine that is under development uses a new hydrogen peroxide-based inactivation method that preserves neutralizing epitopes on the virion better than conventional methods (Mark Slifka, personal communication) [<xref rid="B131-vaccines-07-00179" ref-type="bibr">131</xref>]. It is possible that this improved inactivation method will result in a vaccine that induces protective immunity after a single dose, but that remains to be determined. </p><p>A second approach to produce a safer YF vaccine is to express the YFV pre-M and E proteins either as recombinant proteins or in another safer viral vector. The most advanced vaccine of this type utilizes the replication-defective Modified Vaccinia Ankara (MVA) vector [<xref rid="B132-vaccines-07-00179" ref-type="bibr">132</xref>]. This vaccine has been shown to induce protective immunity in small animal models and is currently being evaluated in a Phase I trial in humans [<xref rid="B133-vaccines-07-00179" ref-type="bibr">133</xref>].</p></sec><sec id="sec10-vaccines-07-00179"><title>10. Summary Points</title><p>YF is a potentially fatal, mosquito-borne viral disease that appears to be experiencing a resurgence in endemic areas in Africa and South America and spreading to non-endemic areas despite an effective vaccine. With increasing globalization and mobility, YFV has the potential to spread to YFV-na&#x000ef;ve regions in Asia that have ideal ecological conditions to sustain viral transmission.</p><p>In response to the recent resurgence in YF, the EYE strategy was developed by WHO, Gavi, the Vaccine Alliance and UNICEF in collaboration with 50 other partners to vaccinate at-risk populations, mitigate outbreaks and prevent the spread of the disease. In order to do this, 80% of the population in risk areas need to be vaccinated, surveillance and laboratory capacity strengthened, and newer methods to predict emerging risk areas developed and utilized. This means that an adequate supply of YF vaccine needs to be made available.</p><p>YF 17D vaccines are effective and safe for most people. However, with an aging population throughout much of the tropics, a new vaccine with a better safety profile in person &#x0003e;60 years is desirable. In addition, a new vaccine with robust production capacity is needed to keep up with the demand as demonstrated by the recent outbreaks in DRC and Brazil in which fractional dosing had to be used. Two vaccine development approaches are being investigated to address production capacity and safety: inactivated whole virus vaccines using the 17D virus produced in cell culture and replication-defective MVA vector vaccine expressing the YFV pre-M and E proteins.</p></sec></body><back><notes><title>Author Contributions</title><p>All authors contributed substantially to the work reported.</p></notes><notes><title>Funding</title><p>This research received no external funding.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-07-00179"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y.J.S.</given-names></name><name><surname>Higgs</surname><given-names>S.</given-names></name><name><surname>Vanlandingham</surname><given-names>D.L.</given-names></name></person-group><article-title>Emergence and re-emergence of mosquito-borne arboviruses</article-title><source>Curr. Opin. Virol.</source><year>2019</year><volume>34</volume><fpage>104</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2019.01.001</pub-id><?supplied-pmid 30743191?><pub-id pub-id-type="pmid">30743191</pub-id></element-citation></ref><ref id="B2-vaccines-07-00179"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamlet</surname><given-names>A.</given-names></name><name><surname>Jean</surname><given-names>K.</given-names></name><name><surname>Perea</surname><given-names>W.</given-names></name><name><surname>Yactayo</surname><given-names>S.</given-names></name><name><surname>Biey</surname><given-names>J.</given-names></name><name><surname>Van Kerkhove</surname><given-names>M.</given-names></name><name><surname>Ferguson</surname><given-names>N.</given-names></name><name><surname>Garske</surname><given-names>T.</given-names></name></person-group><article-title>The seasonal influence of climate and environment on yellow fever transmission across Africa</article-title><source>PLoS Negl. Trop. Dis.</source><year>2018</year><volume>12</volume><elocation-id>e0006284</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0006284</pub-id><?supplied-pmid 29543798?><pub-id pub-id-type="pmid">29543798</pub-id></element-citation></ref><ref id="B3-vaccines-07-00179"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weetman</surname><given-names>D.</given-names></name><name><surname>Kamgang</surname><given-names>B.</given-names></name><name><surname>Badolo</surname><given-names>A.</given-names></name><name><surname>Moyes</surname><given-names>C.L.</given-names></name><name><surname>Shearer</surname><given-names>F.M.</given-names></name><name><surname>Coulibaly</surname><given-names>M.</given-names></name><name><surname>Pinto</surname><given-names>J.</given-names></name><name><surname>Lambrechts</surname><given-names>L.</given-names></name><name><surname>McCall</surname><given-names>P.J.</given-names></name></person-group><article-title>Aedes Mosquitoes and Aedes-Borne Arboviruses in Africa: Current and Future Threats</article-title><source>Int. J. Environ. Res. Public Health</source><year>2018</year><volume>15</volume><elocation-id>220</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph15020220</pub-id><?supplied-pmid 29382107?><pub-id pub-id-type="pmid">29382107</pub-id></element-citation></ref><ref id="B4-vaccines-07-00179"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamrick</surname><given-names>P.N.</given-names></name><name><surname>Aldighieri</surname><given-names>S.</given-names></name><name><surname>Machado</surname><given-names>G.</given-names></name><name><surname>Leonel</surname><given-names>D.G.</given-names></name><name><surname>Vilca</surname><given-names>L.M.</given-names></name><name><surname>Uriona</surname><given-names>S.</given-names></name><name><surname>Schneider</surname><given-names>M.C.</given-names></name></person-group><article-title>Geographic patterns and environmental factors associated with human yellow fever presence in the Americas</article-title><source>PLoS Negl. Trop. Dis.</source><year>2017</year><volume>11</volume><pub-id pub-id-type="doi">10.1371/journal.pntd.0005897</pub-id></element-citation></ref><ref id="B5-vaccines-07-00179"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abreu</surname><given-names>F.V.S.</given-names></name><name><surname>Ribeiro</surname><given-names>I.P.</given-names></name><name><surname>Ferreira-de-Brito</surname><given-names>A.</given-names></name><name><surname>Santos</surname><given-names>A.</given-names></name><name><surname>Miranda</surname><given-names>R.M.</given-names></name><name><surname>Bonelly</surname><given-names>I.S.</given-names></name><name><surname>Neves</surname><given-names>M.</given-names></name><name><surname>Bersot</surname><given-names>M.I.</given-names></name><name><surname>Santos</surname><given-names>T.P.D.</given-names></name><name><surname>Gomes</surname><given-names>M.Q.</given-names></name><etal/></person-group><article-title>Haemagogus leucocelaenus and Haemagogus janthinomys are the primary vectors in the major yellow fever outbreak in Brazil, 2016&#x02013;2018</article-title><source>Emerg. Microbes Infect.</source><year>2019</year><volume>8</volume><fpage>218</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1080/22221751.2019.1568180</pub-id><pub-id pub-id-type="pmid">30866775</pub-id></element-citation></ref><ref id="B6-vaccines-07-00179"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>A.D.T.</given-names></name></person-group><article-title>The reemergence of yellow fever</article-title><source>Science</source><year>2018</year><volume>361</volume><fpage>847</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1126/science.aau8225</pub-id><pub-id pub-id-type="pmid">30139914</pub-id></element-citation></ref><ref id="B7-vaccines-07-00179"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wamala</surname><given-names>J.F.</given-names></name><name><surname>Malimbo</surname><given-names>M.</given-names></name><name><surname>Okot</surname><given-names>C.L.</given-names></name><name><surname>Atai-Omoruto</surname><given-names>A.D.</given-names></name><name><surname>Tenywa</surname><given-names>E.</given-names></name><name><surname>Miller</surname><given-names>J.R.</given-names></name><name><surname>Balinandi</surname><given-names>S.</given-names></name><name><surname>Shoemaker</surname><given-names>T.</given-names></name><name><surname>Oyoo</surname><given-names>C.</given-names></name><name><surname>Omony</surname><given-names>E.O.</given-names></name><etal/></person-group><article-title>Epidemiological and laboratory characterization of a yellow fever outbreak in northern Uganda, October 2010&#x02013;January 2011</article-title><source>Int. J. Infect. Dis.</source><year>2012</year><volume>16</volume><fpage>e536</fpage><lpage>e542</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2012.03.004</pub-id><pub-id pub-id-type="pmid">22575876</pub-id></element-citation></ref><ref id="B8-vaccines-07-00179"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwagonza</surname><given-names>L.</given-names></name><name><surname>Masiira</surname><given-names>B.</given-names></name><name><surname>Kyobe-Bosa</surname><given-names>H.</given-names></name><name><surname>Kadobera</surname><given-names>D.</given-names></name><name><surname>Atuheire</surname><given-names>E.B.</given-names></name><name><surname>Lubwama</surname><given-names>B.</given-names></name><name><surname>Kagirita</surname><given-names>A.</given-names></name><name><surname>Katushabe</surname><given-names>E.</given-names></name><name><surname>Kayiwa</surname><given-names>J.T.</given-names></name><name><surname>Lutwama</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Outbreak of yellow fever in central and southwestern Uganda, February-may 2016</article-title><source>BMC Infect. Dis.</source><year>2018</year><volume>18</volume><pub-id pub-id-type="doi">10.1186/s12879-018-3440-y</pub-id></element-citation></ref><ref id="B9-vaccines-07-00179"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lilay</surname><given-names>A.</given-names></name><name><surname>Asamene</surname><given-names>N.</given-names></name><name><surname>Bekele</surname><given-names>A.</given-names></name><name><surname>Mengesha</surname><given-names>M.</given-names></name><name><surname>Wendabeku</surname><given-names>M.</given-names></name><name><surname>Tareke</surname><given-names>I.</given-names></name><name><surname>Girmay</surname><given-names>A.</given-names></name><name><surname>Wuletaw</surname><given-names>Y.</given-names></name><name><surname>Adossa</surname><given-names>A.</given-names></name><name><surname>Ba</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Reemergence of yellow fever in Ethiopia after 50 years, 2013: Epidemiological and entomological investigations</article-title><source>BMC Infect. Dis.</source><year>2017</year><volume>17</volume><elocation-id>343</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-017-2435-4</pub-id><pub-id pub-id-type="pmid">28506254</pub-id></element-citation></ref><ref id="B10-vaccines-07-00179"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grobbelaar</surname><given-names>A.A.</given-names></name><name><surname>Weyer</surname><given-names>J.</given-names></name><name><surname>Moolla</surname><given-names>N.</given-names></name><name><surname>van Vuren</surname><given-names>P.J.</given-names></name><name><surname>Moises</surname><given-names>F.</given-names></name><name><surname>Paweska</surname><given-names>J.T.</given-names></name></person-group><article-title>Resurgence of Yellow Fever in Angola, 2015&#x02013;2016</article-title><source>Emerg. Infect. Dis.</source><year>2016</year><volume>22</volume><fpage>1854</fpage><lpage>1855</lpage><pub-id pub-id-type="doi">10.3201/eid2210.160818</pub-id><pub-id pub-id-type="pmid">27536787</pub-id></element-citation></ref><ref id="B11-vaccines-07-00179"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraemer</surname><given-names>M.U.G.</given-names></name><name><surname>Faria</surname><given-names>N.R.</given-names></name><name><surname>Reiner</surname><given-names>R.C.</given-names><suffix>Jr.</suffix></name><name><surname>Golding</surname><given-names>N.</given-names></name><name><surname>Nikolay</surname><given-names>B.</given-names></name><name><surname>Stasse</surname><given-names>S.</given-names></name><name><surname>Johansson</surname><given-names>M.A.</given-names></name><name><surname>Salje</surname><given-names>H.</given-names></name><name><surname>Faye</surname><given-names>O.</given-names></name><name><surname>Wint</surname><given-names>G.R.W.</given-names></name><etal/></person-group><article-title>Spread of yellow fever virus outbreak in Angola and the Democratic Republic of the Congo 2015&#x02013;16: A modelling study</article-title><source>Lancet Infect. Dis.</source><year>2017</year><volume>17</volume><fpage>330</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(16)30513-8</pub-id><pub-id pub-id-type="pmid">28017559</pub-id></element-citation></ref><ref id="B12-vaccines-07-00179"><label>12.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Nigeria Centre for Disease Control</collab></person-group><source>Weekly Epidemiological Report, Week 52</source><publisher-name>Nigeria Centre for Disease Control</publisher-name><publisher-loc>Abuja, Nigeria</publisher-loc><year>2018</year></element-citation></ref><ref id="B13-vaccines-07-00179"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ingelbeen</surname><given-names>B.</given-names></name><name><surname>Weregemere</surname><given-names>N.A.</given-names></name><name><surname>Noel</surname><given-names>H.</given-names></name><name><surname>Tshapenda</surname><given-names>G.P.</given-names></name><name><surname>Mossoko</surname><given-names>M.</given-names></name><name><surname>Nsio</surname><given-names>J.</given-names></name><name><surname>Ronsse</surname><given-names>A.</given-names></name><name><surname>Ahuka-Mundeke</surname><given-names>S.</given-names></name><name><surname>Cohuet</surname><given-names>S.</given-names></name><name><surname>Kebela</surname><given-names>B.I.</given-names></name></person-group><article-title>Urban yellow fever outbreak-Democratic Republic of the Congo, 2016: Towards more rapid case detection</article-title><source>PLoS Negl. Trop. Dis.</source><year>2018</year><volume>12</volume><pub-id pub-id-type="doi">10.1371/journal.pntd.0007029</pub-id><?supplied-pmid 30532188?><pub-id pub-id-type="pmid">30532188</pub-id></element-citation></ref><ref id="B14-vaccines-07-00179"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>Q.A.</given-names></name><name><surname>Memish</surname><given-names>Z.A.</given-names></name></person-group><article-title>Yellow fever from Angola and Congo: A storm gathers</article-title><source>Trop. Doct.</source><year>2017</year><volume>47</volume><fpage>92</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1177/0049475517699726</pub-id><?supplied-pmid 28424031?><pub-id pub-id-type="pmid">28424031</pub-id></element-citation></ref><ref id="B15-vaccines-07-00179"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>Q.</given-names></name><name><surname>Hu</surname><given-names>Y.W.</given-names></name><name><surname>Zhu</surname><given-names>A.H.</given-names></name><name><surname>Ye</surname><given-names>S.K.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Lu</surname><given-names>H.Z.</given-names></name></person-group><article-title>Yellow Fever in a Worker. Returning to China from Angola, March 2016</article-title><source>Emerg. Infect. Dis.</source><year>2016</year><volume>22</volume><fpage>1317</fpage><lpage>1318</lpage><pub-id pub-id-type="doi">10.3201/eid2207.160469</pub-id><?supplied-pmid 27314417?><pub-id pub-id-type="pmid">27314417</pub-id></element-citation></ref><ref id="B16-vaccines-07-00179"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>S.J.</given-names></name><name><surname>Pan</surname><given-names>Y.</given-names></name><name><surname>Lyu</surname><given-names>Y.N.</given-names></name><name><surname>Liang</surname><given-names>Z.C.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>Y.L.</given-names></name><name><surname>Dou</surname><given-names>X.F.</given-names></name><name><surname>Tian</surname><given-names>L.L.</given-names></name><name><surname>Huo</surname><given-names>D.</given-names></name><name><surname>Chen</surname><given-names>L.J.</given-names></name><etal/></person-group><article-title>Detection of yellow fever virus genomes from four imported cases in China</article-title><source>Int. J. Infect. Dis.</source><year>2017</year><volume>60</volume><fpage>93</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2017.05.001</pub-id><?supplied-pmid 28623054?><pub-id pub-id-type="pmid">28623054</pub-id></element-citation></ref><ref id="B17-vaccines-07-00179"><label>17.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Pan American Health Organization/World Health Organization</collab></person-group><source>Epidemiological Update: Yellow Fever. 6 March 2019</source><publisher-name>PAHO/WHO</publisher-name><publisher-loc>Washington, DC, USA</publisher-loc><year>2019</year></element-citation></ref><ref id="B18-vaccines-07-00179"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinheiro</surname><given-names>G.G.</given-names></name><name><surname>Rocha</surname><given-names>M.N.</given-names></name><name><surname>de Oliveira</surname><given-names>M.A.</given-names></name><name><surname>Moreira</surname><given-names>L.A.</given-names></name><name><surname>Andrade Filho</surname><given-names>J.D.</given-names></name></person-group><article-title>Detection of Yellow Fever Virus in Sylvatic Mosquitoes during Disease Outbreaks of 2017&#x02013;2018 in Minas Gerais State, Brazil</article-title><source>Insects</source><year>2019</year><volume>10</volume><elocation-id>136</elocation-id><pub-id pub-id-type="doi">10.3390/insects10050136</pub-id></element-citation></ref><ref id="B19-vaccines-07-00179"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dexheimer Paploski</surname><given-names>I.A.</given-names></name><name><surname>Souza</surname><given-names>R.L.</given-names></name><name><surname>Tauro</surname><given-names>L.B.</given-names></name><name><surname>Cardoso</surname><given-names>C.W.</given-names></name><name><surname>Mugabe</surname><given-names>V.A.</given-names></name><name><surname>Pereira Simoes Alves</surname><given-names>A.B.</given-names></name><name><surname>de Jesus Gomes</surname><given-names>J.</given-names></name><name><surname>Kikuti</surname><given-names>M.</given-names></name><name><surname>Campos</surname><given-names>G.S.</given-names></name><name><surname>Sardi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Epizootic Outbreak of Yellow Fever Virus and Risk for Human Disease in Salvador, Brazil</article-title><source>Ann. Intern. Med.</source><year>2018</year><volume>168</volume><fpage>301</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.7326/M17-1949</pub-id><pub-id pub-id-type="pmid">29114780</pub-id></element-citation></ref><ref id="B20-vaccines-07-00179"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moussallem</surname><given-names>T.M.</given-names></name><name><surname>Gava</surname><given-names>C.</given-names></name><name><surname>Ardisson</surname><given-names>K.S.</given-names></name><name><surname>Marques</surname><given-names>C.S.</given-names></name><name><surname>Graceli</surname><given-names>G.C.</given-names></name><name><surname>Koski</surname><given-names>A.</given-names></name><name><surname>Almada</surname><given-names>G.L.</given-names></name><name><surname>da Silva</surname><given-names>A.R.</given-names></name><name><surname>de Jesus</surname><given-names>F.A.A.</given-names></name><name><surname>Rodrigues</surname><given-names>G.A.P.</given-names></name><etal/></person-group><article-title>Yellow fever outbreak in a rural-urban mixed community of Espirito Santo, Brazil: Epidemiological aspects</article-title><source>Revista Panamericana de Salud P&#x000fa;blica</source><year>2019</year><volume>43</volume><fpage>e29</fpage><pub-id pub-id-type="doi">10.26633/RPSP.2019.29</pub-id><pub-id pub-id-type="pmid">31093253</pub-id></element-citation></ref><ref id="B21-vaccines-07-00179"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gossner</surname><given-names>C.M.</given-names></name><name><surname>Haussig</surname><given-names>J.M.</given-names></name><name><surname>de Bellegarde de Saint Lary</surname><given-names>C.</given-names></name><name><surname>Kaasik Aaslav</surname><given-names>K.</given-names></name><name><surname>Schlagenhauf</surname><given-names>P.</given-names></name><name><surname>Sudre</surname><given-names>B.</given-names></name></person-group><article-title>Increased risk of yellow fever infections among unvaccinated European travellers due to ongoing outbreak in Brazil, July 2017 to March 2018</article-title><source>Eurosurveillance</source><year>2018</year><volume>23</volume><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2018.23.11.18-00106</pub-id></element-citation></ref><ref id="B22-vaccines-07-00179"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delatorre</surname><given-names>E.</given-names></name><name><surname>de Abreu</surname><given-names>F.V.S.</given-names></name><name><surname>Ribeiro</surname><given-names>I.P.</given-names></name><name><surname>Gomez</surname><given-names>M.M.</given-names></name><name><surname>Dos Santos</surname><given-names>A.A.C.</given-names></name><name><surname>Ferreira-de-Brito</surname><given-names>A.</given-names></name><name><surname>Neves</surname><given-names>M.</given-names></name><name><surname>Bonelly</surname><given-names>I.</given-names></name><name><surname>de Miranda</surname><given-names>R.M.</given-names></name><name><surname>Furtado</surname><given-names>N.D.</given-names></name><etal/></person-group><article-title>Distinct YFV Lineages Co-circulated in the Central-Western and Southeastern Brazilian Regions from 2015 to 2018</article-title><source>Front. Microbiol.</source><year>2019</year><volume>10</volume><fpage>1079</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2019.01079</pub-id><pub-id pub-id-type="pmid">31178835</pub-id></element-citation></ref><ref id="B23-vaccines-07-00179"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amaku</surname><given-names>M.</given-names></name><name><surname>Coutinho</surname><given-names>F.A.</given-names></name><name><surname>Massad</surname><given-names>E.</given-names></name></person-group><article-title>Why dengue and yellow fever coexist in some areas of the world and not in others?</article-title><source>Biosystems</source><year>2011</year><volume>106</volume><fpage>111</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.biosystems.2011.07.004</pub-id><?supplied-pmid 21839800?><pub-id pub-id-type="pmid">21839800</pub-id></element-citation></ref><ref id="B24-vaccines-07-00179"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Possas</surname><given-names>C.</given-names></name><name><surname>Lourenco-de-Oliveira</surname><given-names>R.</given-names></name><name><surname>Tauil</surname><given-names>P.L.</given-names></name><name><surname>Pinheiro</surname><given-names>F.P.</given-names></name><name><surname>Pissinatti</surname><given-names>A.</given-names></name><name><surname>Cunha</surname><given-names>R.V.D.</given-names></name><name><surname>Freire</surname><given-names>M.</given-names></name><name><surname>Martins</surname><given-names>R.M.</given-names></name><name><surname>Homma</surname><given-names>A.</given-names></name></person-group><article-title>Yellow fever outbreak in Brazil: The puzzle of rapid viral spread and challenges for immunisation</article-title><source>Mem&#x000f3;rias do Instituto Oswaldo Cruz</source><year>2018</year><volume>113</volume><fpage>e180278</fpage><pub-id pub-id-type="doi">10.1590/0074-02760180278</pub-id><?supplied-pmid 30427974?><pub-id pub-id-type="pmid">30427974</pub-id></element-citation></ref><ref id="B25-vaccines-07-00179"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massad</surname><given-names>E.</given-names></name><name><surname>Amaku</surname><given-names>M.</given-names></name><name><surname>Coutinho</surname><given-names>F.A.B.</given-names></name><name><surname>Struchiner</surname><given-names>C.J.</given-names></name><name><surname>Lopez</surname><given-names>L.F.</given-names></name><name><surname>Wilder-Smith</surname><given-names>A.</given-names></name><name><surname>Burattini</surname><given-names>M.N.</given-names></name></person-group><article-title>Estimating the size of Aedes aegypti populations from dengue incidence data: Implications for the risk of yellow fever outbreaks</article-title><source>Infect. Dis. Model.</source><year>2017</year><volume>2</volume><fpage>441</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1016/j.idm.2017.12.001</pub-id><?supplied-pmid 30137722?><pub-id pub-id-type="pmid">30137722</pub-id></element-citation></ref><ref id="B26-vaccines-07-00179"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorigatti</surname><given-names>I.</given-names></name><name><surname>Hamlet</surname><given-names>A.</given-names></name><name><surname>Aguas</surname><given-names>R.</given-names></name><name><surname>Cattarino</surname><given-names>L.</given-names></name><name><surname>Cori</surname><given-names>A.</given-names></name><name><surname>Donnelly</surname><given-names>C.A.</given-names></name><name><surname>Garske</surname><given-names>T.</given-names></name><name><surname>Imai</surname><given-names>N.</given-names></name><name><surname>Ferguson</surname><given-names>N.M.</given-names></name></person-group><article-title>International risk of yellow fever spread from the ongoing outbreak in Brazil, December 2016 to May 2017</article-title><source>Eurosurveill</source><year>2017</year><volume>22</volume><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2017.22.28.30572</pub-id><?supplied-pmid 28749337?><pub-id pub-id-type="pmid">28749337</pub-id></element-citation></ref><ref id="B27-vaccines-07-00179"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamer</surname><given-names>D.H.</given-names></name><name><surname>Angelo</surname><given-names>K.</given-names></name><name><surname>Caumes</surname><given-names>E.</given-names></name><name><surname>van Genderen</surname><given-names>P.J.J.</given-names></name><name><surname>Florescu</surname><given-names>S.A.</given-names></name><name><surname>Popescu</surname><given-names>C.P.</given-names></name><name><surname>Perret</surname><given-names>C.</given-names></name><name><surname>McBride</surname><given-names>A.</given-names></name><name><surname>Checkley</surname><given-names>A.</given-names></name><name><surname>Ryan</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Fatal Yellow Fever in Travelers to Brazil, 2018</article-title><source>Morb. Mortal. Wkly. Rep.</source><year>2018</year><volume>67</volume><fpage>340</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm6711e1</pub-id><?supplied-pmid 29565840?><pub-id pub-id-type="pmid">29565840</pub-id></element-citation></ref><ref id="B28-vaccines-07-00179"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brent</surname><given-names>S.E.</given-names></name><name><surname>Watts</surname><given-names>A.</given-names></name><name><surname>Cetron</surname><given-names>M.</given-names></name><name><surname>German</surname><given-names>M.</given-names></name><name><surname>Kraemer</surname><given-names>M.U.</given-names></name><name><surname>Bogoch</surname><given-names>I.I.</given-names></name><name><surname>Brady</surname><given-names>O.J.</given-names></name><name><surname>Hay</surname><given-names>S.I.</given-names></name><name><surname>Creatore</surname><given-names>M.I.</given-names></name><name><surname>Khan</surname><given-names>K.</given-names></name></person-group><article-title>International travel between global urban centres vulnerable to yellow fever transmission</article-title><source>Bull. World Health Organ.</source><year>2018</year><volume>96</volume><fpage>343B</fpage><lpage>354B</lpage><pub-id pub-id-type="doi">10.2471/BLT.17.205658</pub-id><pub-id pub-id-type="pmid">29875519</pub-id></element-citation></ref><ref id="B29-vaccines-07-00179"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasconcelos</surname><given-names>P.F.</given-names></name></person-group><article-title>Yellow fever in Brazil: Thoughts and hypotheses on the emergence in previously free areas</article-title><source>Rev. Saude Publica</source><year>2010</year><volume>44</volume><fpage>1144</fpage><lpage>1149</lpage><pub-id pub-id-type="doi">10.1590/S0034-89102010005000046</pub-id><pub-id pub-id-type="pmid">21109907</pub-id></element-citation></ref><ref id="B30-vaccines-07-00179"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandes</surname><given-names>N.</given-names></name><name><surname>Cunha</surname><given-names>M.S.</given-names></name><name><surname>Guerra</surname><given-names>J.M.</given-names></name><name><surname>Ressio</surname><given-names>R.A.</given-names></name><name><surname>Cirqueira</surname><given-names>C.D.S.</given-names></name><name><surname>Iglezias</surname><given-names>S.D.</given-names></name><name><surname>de Carvalho</surname><given-names>J.</given-names></name><name><surname>Araujo</surname><given-names>E.L.L.</given-names></name><name><surname>Catao-Dias</surname><given-names>J.L.</given-names></name><name><surname>Diaz-Delgado</surname><given-names>J.</given-names></name></person-group><article-title>Outbreak of Yellow Fever among Nonhuman Primates, Espirito Santo, Brazil, 2017</article-title><source>Emerg. Infect. Dis.</source><year>2017</year><volume>23</volume><fpage>2038</fpage><lpage>2041</lpage><pub-id pub-id-type="doi">10.3201/eid2312.170685</pub-id><pub-id pub-id-type="pmid">29148378</pub-id></element-citation></ref><ref id="B31-vaccines-07-00179"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gershman</surname><given-names>M.D.</given-names></name><name><surname>Angelo</surname><given-names>K.M.</given-names></name><name><surname>Ritchey</surname><given-names>J.</given-names></name><name><surname>Greenberg</surname><given-names>D.P.</given-names></name><name><surname>Muhammad</surname><given-names>R.D.</given-names></name><name><surname>Brunette</surname><given-names>G.</given-names></name><name><surname>Cetron</surname><given-names>M.S.</given-names></name><name><surname>Sotir</surname><given-names>M.J.</given-names></name></person-group><article-title>Addressing a Yellow Fever Vaccine Shortage - United States, 2016&#x02013;2017</article-title><source>Morb. Mortal. Wkly. Rep.</source><year>2017</year><volume>66</volume><fpage>457</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm6617e2</pub-id></element-citation></ref><ref id="B32-vaccines-07-00179"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roukens</surname><given-names>A.H.E.</given-names></name><name><surname>Visser</surname><given-names>L.G.</given-names></name></person-group><article-title>Fractional-dose yellow fever vaccination: An expert review</article-title><source>J. Travel Med.</source><year>2019</year><fpage>26</fpage><pub-id pub-id-type="doi">10.1093/jtm/taz024</pub-id></element-citation></ref><ref id="B33-vaccines-07-00179"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>Eliminate yellow fever epidemics (EYE): A global strategy, 2017&#x02013;2026</article-title><source>Wkly. Epidemiol. Rec.</source><year>2017</year><volume>16</volume><fpage>193</fpage><lpage>204</lpage></element-citation></ref><ref id="B34-vaccines-07-00179"><label>34.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>Division of Epidemiological Surveillance and Health Situation Trend Assessment</article-title><source>Global Health Situation and Projections&#x02014;Estimates</source><publisher-name>WHO</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>1992</year></element-citation></ref><ref id="B35-vaccines-07-00179"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garske</surname><given-names>T.</given-names></name><name><surname>Van Kerkhove</surname><given-names>M.D.</given-names></name><name><surname>Yactayo</surname><given-names>S.</given-names></name><name><surname>Ronveaux</surname><given-names>O.</given-names></name><name><surname>Lewis</surname><given-names>R.F.</given-names></name><name><surname>Staples</surname><given-names>J.E.</given-names></name><name><surname>Perea</surname><given-names>W.</given-names></name><name><surname>Ferguson</surname><given-names>N.M.</given-names></name><collab>Yellow Fever Expert Committee</collab></person-group><article-title>Yellow Fever in Africa: Estimating the burden of disease and impact of mass vaccination from outbreak and serological data</article-title><source>PLoS Med.</source><year>2014</year><volume>11</volume><fpage>e1001638</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.1001638</pub-id><?supplied-pmid 24800812?><pub-id pub-id-type="pmid">24800812</pub-id></element-citation></ref><ref id="B36-vaccines-07-00179"><label>36.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>PAHO-WHO Member States</collab></person-group><article-title>Member States Reports to Health Emergency Information &#x00026; Risk Assessment Unit (HIM) PAHO Health Emergencies Department (PHE): PAHO&#x02013;WHO; 2019</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://ais.paho.org/phip/viz/ed_yellowfever.asp">http://ais.paho.org/phip/viz/ed_yellowfever.asp</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-10-25">(accessed on 25 October 2019)</date-in-citation></element-citation></ref><ref id="B37-vaccines-07-00179"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>M.A.</given-names></name><name><surname>Arana-Vizcarrondo</surname><given-names>N.</given-names></name><name><surname>Biggerstaff</surname><given-names>B.J.</given-names></name><name><surname>Staples</surname><given-names>J.E.</given-names></name></person-group><article-title>Incubation periods of Yellow fever virus</article-title><source>Am. J. Trop. Med. Hyg.</source><year>2010</year><volume>83</volume><fpage>183</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.2010.09-0782</pub-id><?supplied-pmid 20595499?><pub-id pub-id-type="pmid">20595499</pub-id></element-citation></ref><ref id="B38-vaccines-07-00179"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>M.A.</given-names></name><name><surname>Vasconcelos</surname><given-names>P.F.</given-names></name><name><surname>Staples</surname><given-names>J.E.</given-names></name></person-group><article-title>The whole iceberg: Estimating the incidence of yellow fever virus infection from the number of severe cases</article-title><source>Trans. R. Soc. Trop. Med. Hyg.</source><year>2014</year><volume>108</volume><fpage>482</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1093/trstmh/tru092</pub-id><pub-id pub-id-type="pmid">24980556</pub-id></element-citation></ref><ref id="B39-vaccines-07-00179"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kallas</surname><given-names>E.G.</given-names></name><name><surname>D&#x02019;Elia Zanella</surname><given-names>L.</given-names></name><name><surname>Moreira</surname><given-names>C.H.V.</given-names></name><name><surname>Buccheri</surname><given-names>R.</given-names></name><name><surname>Diniz</surname><given-names>G.B.F.</given-names></name><name><surname>Castineiras</surname><given-names>A.C.P.</given-names></name><name><surname>Costa</surname><given-names>P.R.</given-names></name><name><surname>Dias</surname><given-names>J.Z.C.</given-names></name><name><surname>Marmorato</surname><given-names>M.P.</given-names></name><name><surname>Song</surname><given-names>A.T.W.</given-names></name><etal/></person-group><article-title>Predictors of mortality in patients with yellow fever: An observational cohort study</article-title><source>Lancet Infect. Dis.</source><year>2019</year><volume>19</volume><fpage>750</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(19)30125-2</pub-id><pub-id pub-id-type="pmid">31104909</pub-id></element-citation></ref><ref id="B40-vaccines-07-00179"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuboi</surname><given-names>S.H.</given-names></name><name><surname>Costa</surname><given-names>Z.G.</given-names></name><name><surname>da Costa Vasconcelos</surname><given-names>P.F.</given-names></name><name><surname>Hatch</surname><given-names>D.</given-names></name></person-group><article-title>Clinical and epidemiological characteristics of yellow fever in Brazil: Analysis of reported cases 1998-2002</article-title><source>Trans. R. Soc. Trop. Med. Hyg.</source><year>2007</year><volume>101</volume><fpage>169</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/j.trstmh.2006.04.001</pub-id><pub-id pub-id-type="pmid">16814821</pub-id></element-citation></ref><ref id="B41-vaccines-07-00179"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casadio</surname><given-names>L.V.B.</given-names></name><name><surname>Salles</surname><given-names>A.P.M.</given-names></name><name><surname>Malta</surname><given-names>F.M.</given-names></name><name><surname>Leite</surname><given-names>G.F.</given-names></name><name><surname>Ho</surname><given-names>Y.L.</given-names></name><name><surname>Gomes-Gouvea</surname><given-names>M.S.</given-names></name><name><surname>Malbouisson</surname><given-names>L.M.S.</given-names></name><name><surname>Levin</surname><given-names>A.S.</given-names></name><name><surname>de Azevedo Neto</surname><given-names>R.S.</given-names></name><name><surname>Carrilho</surname><given-names>F.J.</given-names></name><etal/></person-group><article-title>Lipase and factor V (but not viral load) are prognostic factors for the evolution of severe yellow fever cases</article-title><source>Mem&#x000f3;rias do Instituto Oswaldo Cruz</source><year>2019</year><volume>114</volume><fpage>e190033</fpage><pub-id pub-id-type="doi">10.1590/0074-02760190033</pub-id><pub-id pub-id-type="pmid">31116245</pub-id></element-citation></ref><ref id="B42-vaccines-07-00179"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duarte-Neto</surname><given-names>A.N.</given-names></name><name><surname>Cunha</surname><given-names>M.D.P.</given-names></name><name><surname>Marcilio</surname><given-names>I.</given-names></name><name><surname>Song</surname><given-names>A.T.W.</given-names></name><name><surname>de Martino</surname><given-names>R.B.</given-names></name><name><surname>Ho</surname><given-names>Y.L.</given-names></name><name><surname>Pour</surname><given-names>S.Z.</given-names></name><name><surname>Dolhnikoff</surname><given-names>M.</given-names></name><name><surname>Saldiva</surname><given-names>P.H.N.</given-names></name><name><surname>Duarte</surname><given-names>M.I.S.</given-names></name><etal/></person-group><article-title>Yellow fever and orthotopic liver transplantation: New insights from the autopsy room for an old but re-emerging disease</article-title><source>Histopathology</source><year>2019</year><pub-id pub-id-type="doi">10.1111/his.13904</pub-id></element-citation></ref><ref id="B43-vaccines-07-00179"><label>43.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Staples</surname><given-names>J.E.</given-names></name><name><surname>Monath</surname><given-names>T.P.</given-names></name><name><surname>Gershman</surname><given-names>M.D.</given-names></name><name><surname>Barrett</surname><given-names>A.D.</given-names></name></person-group><article-title>Yellow Fever Vaccines</article-title><source>Vaccines</source><edition>7th ed.</edition><person-group person-group-type="editor"><name><surname>Plotkin</surname><given-names>S.A.</given-names></name><name><surname>Orenstein</surname><given-names>W.A.</given-names></name><name><surname>Offit</surname><given-names>P.A.</given-names></name></person-group><publisher-name>Elsevier</publisher-name><publisher-loc>Philadelphia, PA, USA</publisher-loc><year>2018</year><fpage>1181</fpage><lpage>1265</lpage></element-citation></ref><ref id="B44-vaccines-07-00179"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monath</surname><given-names>T.P.</given-names></name><name><surname>Cropp</surname><given-names>C.B.</given-names></name><name><surname>Muth</surname><given-names>D.J.</given-names></name><name><surname>Calisher</surname><given-names>C.H.</given-names></name></person-group><article-title>Indirect fluorescent antibody test for the diagnosis of yellow fever</article-title><source>Trans. R. Soc. Trop. Med. Hyg.</source><year>1981</year><volume>75</volume><fpage>282</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1016/0035-9203(81)90335-7</pub-id><pub-id pub-id-type="pmid">7029803</pub-id></element-citation></ref><ref id="B45-vaccines-07-00179"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyaji</surname><given-names>K.T.</given-names></name><name><surname>Avelino-Silva</surname><given-names>V.I.</given-names></name><name><surname>Simoes</surname><given-names>M.</given-names></name><name><surname>Freire</surname><given-names>M.D.</given-names></name><name><surname>Medeiros</surname><given-names>C.R.</given-names></name><name><surname>Braga</surname><given-names>P.E.</given-names></name><name><surname>Neves</surname><given-names>M.A.</given-names></name><name><surname>Lopes</surname><given-names>M.H.</given-names></name><name><surname>Kallas</surname><given-names>E.G.</given-names></name><name><surname>Sartori</surname><given-names>A.M.</given-names></name></person-group><article-title>Prevalence and titers of yellow fever virus neutralizing antibodies in previously vaccinated adults</article-title><source>Rev. Inst. Med. Trop. Sao Paulo</source><year>2017</year><volume>59</volume><fpage>e2</fpage><pub-id pub-id-type="doi">10.1590/s1678-9946201759002</pub-id><pub-id pub-id-type="pmid">28380113</pub-id></element-citation></ref><ref id="B46-vaccines-07-00179"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campi-Azevedo</surname><given-names>A.C.</given-names></name><name><surname>Peruhype-Magalhaes</surname><given-names>V.</given-names></name><name><surname>Coelho-Dos-Reis</surname><given-names>J.G.</given-names></name><name><surname>Antonelli</surname><given-names>L.R.</given-names></name><name><surname>Costa-Pereira</surname><given-names>C.</given-names></name><name><surname>Speziali</surname><given-names>E.</given-names></name><name><surname>Reis</surname><given-names>L.R.</given-names></name><name><surname>Lemos</surname><given-names>J.A.</given-names></name><name><surname>Ribeiro</surname><given-names>J.G.L.</given-names></name><name><surname>Bastos Camacho</surname><given-names>L.A.</given-names></name><etal/></person-group><article-title>17DD Yellow Fever Revaccination and Heightened Long-Term Immunity in Populations of Disease-Endemic Areas, Brazil</article-title><source>Emerg. Infect. Dis.</source><year>2019</year><volume>25</volume><fpage>1511</fpage><lpage>1521</lpage><pub-id pub-id-type="doi">10.3201/eid2508.181432</pub-id><?supplied-pmid 31298654?><pub-id pub-id-type="pmid">31298654</pub-id></element-citation></ref><ref id="B47-vaccines-07-00179"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawyer</surname><given-names>W.A.</given-names></name><name><surname>Lloyd</surname><given-names>W.</given-names></name></person-group><article-title>The Use of Mice in Tests of Immunity against Yellow Fever</article-title><source>J. Exp. Med.</source><year>1931</year><volume>54</volume><fpage>533</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1084/jem.54.4.533</pub-id><?supplied-pmid 19869938?><pub-id pub-id-type="pmid">19869938</pub-id></element-citation></ref><ref id="B48-vaccines-07-00179"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>J.H.</given-names></name><name><surname>Hudson</surname><given-names>N.P.</given-names></name></person-group><article-title>Duration of immunity in human yellow fever as shown by protective power of serum</article-title><source>J. Prev. Med.</source><year>1930</year><volume>4</volume><fpage>177</fpage><lpage>178</lpage></element-citation></ref><ref id="B49-vaccines-07-00179"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blake</surname><given-names>L.E.</given-names></name><name><surname>Garcia-Blanco</surname><given-names>M.A.</given-names></name></person-group><article-title>Human genetic variation and yellow fever mortality during 19th century U.S. epidemics</article-title><source>mBio</source><year>2014</year><volume>5</volume><fpage>e01253-14</fpage><pub-id pub-id-type="doi">10.1128/mBio.01253-14</pub-id><?supplied-pmid 24895309?><pub-id pub-id-type="pmid">24895309</pub-id></element-citation></ref><ref id="B50-vaccines-07-00179"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>R.A.</given-names></name><name><surname>de Oliveira-Filho</surname><given-names>E.F.</given-names></name><name><surname>Fernandes</surname><given-names>A.I.</given-names></name><name><surname>Brito</surname><given-names>C.A.</given-names></name><name><surname>Marques</surname><given-names>E.T.</given-names></name><name><surname>Tenorio</surname><given-names>M.C.</given-names></name><name><surname>Gil</surname><given-names>L.H.</given-names></name></person-group><article-title>Previous dengue or Zika virus exposure can drive to infection enhancement or neutralisation of other flaviviruses</article-title><source>Mem&#x000f3;rias do Instituto Oswaldo Cruz</source><year>2019</year><volume>114</volume><fpage>e190098</fpage><pub-id pub-id-type="doi">10.1590/0074-02760190098</pub-id><pub-id pub-id-type="pmid">31411310</pub-id></element-citation></ref><ref id="B51-vaccines-07-00179"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Izurieta</surname><given-names>R.O.</given-names></name><name><surname>Macaluso</surname><given-names>M.</given-names></name><name><surname>Watts</surname><given-names>D.M.</given-names></name><name><surname>Tesh</surname><given-names>R.B.</given-names></name><name><surname>Guerra</surname><given-names>B.</given-names></name><name><surname>Cruz</surname><given-names>L.M.</given-names></name><name><surname>Galwankar</surname><given-names>S.</given-names></name><name><surname>Vermund</surname><given-names>S.H.</given-names></name></person-group><article-title>Anamnestic immune response to dengue and decreased severity of yellow Fever</article-title><source>J. Glob. Infect. Dis.</source><year>2009</year><volume>1</volume><fpage>111</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.4103/0974-777X.56257</pub-id><pub-id pub-id-type="pmid">20300401</pub-id></element-citation></ref><ref id="B52-vaccines-07-00179"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monath</surname><given-names>T.P.</given-names></name></person-group><article-title>Treatment of yellow fever</article-title><source>Antivir. Res.</source><year>2008</year><volume>78</volume><fpage>116</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2007.10.009</pub-id><pub-id pub-id-type="pmid">18061688</pub-id></element-citation></ref><ref id="B53-vaccines-07-00179"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>Y.L.</given-names></name><name><surname>Joelsons</surname><given-names>D.</given-names></name><name><surname>Leite</surname><given-names>G.F.C.</given-names></name><name><surname>Malbouisson</surname><given-names>L.M.S.</given-names></name><name><surname>Song</surname><given-names>A.T.W.</given-names></name><name><surname>Perondi</surname><given-names>B.</given-names></name><name><surname>Andrade</surname><given-names>L.C.</given-names></name><name><surname>Pinto</surname><given-names>L.F.</given-names></name><name><surname>D&#x02019;Albuquerque</surname><given-names>L.A.C.</given-names></name><name><surname>Segurado</surname><given-names>A.A.C.</given-names></name><etal/></person-group><article-title>Severe yellow fever in Brazil: Clinical characteristics and management</article-title><source>J. Travel Med.</source><year>2019</year><volume>26</volume><pub-id pub-id-type="doi">10.1093/jtm/taz040</pub-id></element-citation></ref><ref id="B54-vaccines-07-00179"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zandi</surname><given-names>K.</given-names></name><name><surname>Amblard</surname><given-names>F.</given-names></name><name><surname>Amichai</surname><given-names>S.</given-names></name><name><surname>Bassit</surname><given-names>L.</given-names></name><name><surname>Tao</surname><given-names>S.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Ollinger Russell</surname><given-names>O.</given-names></name><name><surname>Mengshetti</surname><given-names>S.</given-names></name><name><surname>Schinazi</surname><given-names>R.F.</given-names></name></person-group><article-title>Nucleoside Analogs with Antiviral Activity against Yellow Fever Virus</article-title><source>Antimicrob. Agents Chemother.</source><year>2019</year><volume>63</volume><pub-id pub-id-type="doi">10.1128/AAC.00889-19</pub-id></element-citation></ref><ref id="B55-vaccines-07-00179"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>F.</given-names></name><name><surname>Wu</surname><given-names>S.</given-names></name><name><surname>Julander</surname><given-names>J.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Kulp</surname><given-names>J.</given-names></name><name><surname>Cuconati</surname><given-names>A.</given-names></name><name><surname>Block</surname><given-names>T.M.</given-names></name><name><surname>Du</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>J.T.</given-names></name><etal/></person-group><article-title>A Novel Benzodiazepine Compound Inhibits Yellow Fever Virus Infection by Specifically Targeting NS4B Protein</article-title><source>J. Virol.</source><year>2016</year><volume>90</volume><fpage>10774</fpage><lpage>10788</lpage><pub-id pub-id-type="doi">10.1128/JVI.01253-16</pub-id><pub-id pub-id-type="pmid">27654301</pub-id></element-citation></ref><ref id="B56-vaccines-07-00179"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Burghgraeve</surname><given-names>T.</given-names></name><name><surname>Selisko</surname><given-names>B.</given-names></name><name><surname>Kaptein</surname><given-names>S.</given-names></name><name><surname>Chatelain</surname><given-names>G.</given-names></name><name><surname>Leyssen</surname><given-names>P.</given-names></name><name><surname>Debing</surname><given-names>Y.</given-names></name><name><surname>Jacobs</surname><given-names>M.</given-names></name><name><surname>Van Aerschot</surname><given-names>A.</given-names></name><name><surname>Canard</surname><given-names>B.</given-names></name><name><surname>Neyts</surname><given-names>J.</given-names></name></person-group><article-title>3&#x02032;,5&#x02032;Di-O-trityluridine inhibits in vitro flavivirus replication</article-title><source>Antivir. Res</source><year>2013</year><volume>98</volume><fpage>242</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2013.01.011</pub-id><?supplied-pmid 23470860?><pub-id pub-id-type="pmid">23470860</pub-id></element-citation></ref><ref id="B57-vaccines-07-00179"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Freitas</surname><given-names>C.S.</given-names></name><name><surname>Higa</surname><given-names>L.M.</given-names></name><name><surname>Sacramento</surname><given-names>C.Q.</given-names></name><name><surname>Ferreira</surname><given-names>A.C.</given-names></name><name><surname>Reis</surname><given-names>P.A.</given-names></name><name><surname>Delvecchio</surname><given-names>R.</given-names></name><name><surname>Monteiro</surname><given-names>F.L.</given-names></name><name><surname>Barbosa-Lima</surname><given-names>G.</given-names></name><name><surname>James Westgarth</surname><given-names>H.</given-names></name><name><surname>Vieira</surname><given-names>Y.R.</given-names></name><etal/></person-group><article-title>Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo</article-title><source>PLoS Negl. Trop. Dis.</source><year>2019</year><volume>13</volume><elocation-id>e0007072</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0007072</pub-id><?supplied-pmid 30699122?><pub-id pub-id-type="pmid">30699122</pub-id></element-citation></ref><ref id="B58-vaccines-07-00179"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>T.K.</given-names></name><name><surname>Wells</surname><given-names>J.</given-names></name><name><surname>Panchal</surname><given-names>R.G.</given-names></name><name><surname>Stuthman</surname><given-names>K.S.</given-names></name><name><surname>Garza</surname><given-names>N.L.</given-names></name><name><surname>Van Tongeren</surname><given-names>S.A.</given-names></name><name><surname>Dong</surname><given-names>L.</given-names></name><name><surname>Retterer</surname><given-names>C.J.</given-names></name><name><surname>Eaton</surname><given-names>B.P.</given-names></name><name><surname>Pegoraro</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430</article-title><source>Nature</source><year>2014</year><volume>508</volume><fpage>402</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1038/nature13027</pub-id><?supplied-pmid 24590073?><pub-id pub-id-type="pmid">24590073</pub-id></element-citation></ref><ref id="B59-vaccines-07-00179"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Julander</surname><given-names>J.G.</given-names></name><name><surname>Bantia</surname><given-names>S.</given-names></name><name><surname>Taubenheim</surname><given-names>B.R.</given-names></name><name><surname>Minning</surname><given-names>D.M.</given-names></name><name><surname>Kotian</surname><given-names>P.</given-names></name><name><surname>Morrey</surname><given-names>J.D.</given-names></name><name><surname>Smee</surname><given-names>D.F.</given-names></name><name><surname>Sheridan</surname><given-names>W.P.</given-names></name><name><surname>Babu</surname><given-names>Y.S.</given-names></name></person-group><article-title>BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model</article-title><source>Antimicrob. Agents Chemother.</source><year>2014</year><volume>58</volume><fpage>6607</fpage><lpage>6614</lpage><pub-id pub-id-type="doi">10.1128/AAC.03368-14</pub-id><pub-id pub-id-type="pmid">25155605</pub-id></element-citation></ref><ref id="B60-vaccines-07-00179"><label>60.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>ClinicalTrials.gov</collab></person-group><article-title>A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://ClinicalTrials.gov/show/NCT03891420">https://ClinicalTrials.gov/show/NCT03891420</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-10-25">(accessed on 25 October 2019)</date-in-citation></element-citation></ref><ref id="B61-vaccines-07-00179"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>Y.Q.</given-names></name><name><surname>Dai</surname><given-names>J.X.</given-names></name><name><surname>Ji</surname><given-names>G.H.</given-names></name><name><surname>Jiang</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>H.J.</given-names></name><name><surname>Yang</surname><given-names>H.O.</given-names></name><name><surname>Tan</surname><given-names>W.L.</given-names></name><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Yu</surname><given-names>M.</given-names></name><name><surname>Ge</surname><given-names>B.X.</given-names></name><etal/></person-group><article-title>A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e16059</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0016059</pub-id><pub-id pub-id-type="pmid">21264311</pub-id></element-citation></ref><ref id="B62-vaccines-07-00179"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crill</surname><given-names>W.D.</given-names></name><name><surname>Chang</surname><given-names>G.J.</given-names></name></person-group><article-title>Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes</article-title><source>J. Virol.</source><year>2004</year><volume>78</volume><fpage>13975</fpage><lpage>13986</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.24.13975-13986.2004</pub-id><pub-id pub-id-type="pmid">15564505</pub-id></element-citation></ref><ref id="B63-vaccines-07-00179"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stiasny</surname><given-names>K.</given-names></name><name><surname>Kiermayr</surname><given-names>S.</given-names></name><name><surname>Holzmann</surname><given-names>H.</given-names></name><name><surname>Heinz</surname><given-names>F.X.</given-names></name></person-group><article-title>Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites</article-title><source>J. Virol.</source><year>2006</year><volume>80</volume><fpage>9557</fpage><lpage>9568</lpage><pub-id pub-id-type="doi">10.1128/JVI.00080-06</pub-id><pub-id pub-id-type="pmid">16973559</pub-id></element-citation></ref><ref id="B64-vaccines-07-00179"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goncalvez</surname><given-names>A.P.</given-names></name><name><surname>Purcell</surname><given-names>R.H.</given-names></name><name><surname>Lai</surname><given-names>C.J.</given-names></name></person-group><article-title>Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein</article-title><source>J. Virol.</source><year>2004</year><volume>78</volume><fpage>12919</fpage><lpage>12928</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.23.12919-12928.2004</pub-id><pub-id pub-id-type="pmid">15542644</pub-id></element-citation></ref><ref id="B65-vaccines-07-00179"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Vogt</surname><given-names>M.R.</given-names></name><name><surname>Oliphant</surname><given-names>T.</given-names></name><name><surname>Engle</surname><given-names>M.</given-names></name><name><surname>Bovshik</surname><given-names>E.I.</given-names></name><name><surname>Diamond</surname><given-names>M.S.</given-names></name><name><surname>Beasley</surname><given-names>D.W.</given-names></name></person-group><article-title>Development of resistance to passive therapy with a potently neutralizing humanized monoclonal antibody against West Nile virus</article-title><source>J. Infect. Dis.</source><year>2009</year><volume>200</volume><fpage>202</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1086/599794</pub-id><pub-id pub-id-type="pmid">19527169</pub-id></element-citation></ref><ref id="B66-vaccines-07-00179"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>F.</given-names></name><name><surname>Doyle</surname><given-names>M.</given-names></name><name><surname>Fernandez</surname><given-names>E.</given-names></name><name><surname>Miller</surname><given-names>A.S.</given-names></name><name><surname>Klose</surname><given-names>T.</given-names></name><name><surname>Sevvana</surname><given-names>M.</given-names></name><name><surname>Bryan</surname><given-names>A.</given-names></name><name><surname>Davidson</surname><given-names>E.</given-names></name><name><surname>Doranz</surname><given-names>B.J.</given-names></name><name><surname>Kuhn</surname><given-names>R.J.</given-names></name><etal/></person-group><article-title>Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2019</year><volume>116</volume><fpage>1591</fpage><lpage>1596</lpage><pub-id pub-id-type="doi">10.1073/pnas.1815432116</pub-id><pub-id pub-id-type="pmid">30642974</pub-id></element-citation></ref><ref id="B67-vaccines-07-00179"><label>67.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>ClinicalTrials.gov</collab></person-group><article-title>Safety and Tolerability of an Antibody against Yellow Fever Virus (TY014) in Humans</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://ClinicalTrials.gov/show/NCT03776786">https://ClinicalTrials.gov/show/NCT03776786</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-10-25">(accessed on 25 October 2019)</date-in-citation></element-citation></ref><ref id="B68-vaccines-07-00179"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>Y.H.</given-names></name><name><surname>Kumar</surname><given-names>A.</given-names></name><name><surname>Liew</surname><given-names>C.W.</given-names></name><name><surname>Tharakaraman</surname><given-names>K.</given-names></name><name><surname>Srinivasaraghavan</surname><given-names>K.</given-names></name><name><surname>Sasisekharan</surname><given-names>R.</given-names></name><name><surname>Verma</surname><given-names>C.</given-names></name><name><surname>Lescar</surname><given-names>J.</given-names></name></person-group><article-title>Molecular basis for dengue virus broad cross-neutralization by humanized monoclonal antibody 513</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>8449</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-26800-y</pub-id><?supplied-pmid 29855525?><pub-id pub-id-type="pmid">29855525</pub-id></element-citation></ref><ref id="B69-vaccines-07-00179"><label>69.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gershman</surname><given-names>M.D.</given-names></name><name><surname>Staples</surname><given-names>J.E.</given-names></name></person-group><article-title>Travel-Related Infectious Diseases. Yellow Fever</article-title><source>CDC Yellow Book 2020 Health Information for International Travel</source><person-group person-group-type="editor"><name><surname>Brunette</surname><given-names>G.W.</given-names></name><name><surname>Nemhauser</surname><given-names>J.B.</given-names></name></person-group><publisher-name>Oxford University Press</publisher-name><publisher-loc>Oxford, UK</publisher-loc><year>2019</year></element-citation></ref><ref id="B70-vaccines-07-00179"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaul</surname><given-names>R.B.</given-names></name><name><surname>Evans</surname><given-names>M.V.</given-names></name><name><surname>Murdock</surname><given-names>C.C.</given-names></name><name><surname>Drake</surname><given-names>J.M.</given-names></name></person-group><article-title>Spatio-temporal spillover risk of yellow fever in Brazil</article-title><source>Parasites Vectors</source><year>2018</year><volume>11</volume><fpage>488</fpage><pub-id pub-id-type="doi">10.1186/s13071-018-3063-6</pub-id><?supplied-pmid 30157908?><pub-id pub-id-type="pmid">30157908</pub-id></element-citation></ref><ref id="B71-vaccines-07-00179"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreno</surname><given-names>E.S.</given-names></name><name><surname>Spinola</surname><given-names>R.</given-names></name><name><surname>Tengan</surname><given-names>C.H.</given-names></name><name><surname>Brasil</surname><given-names>R.A.</given-names></name><name><surname>Siciliano</surname><given-names>M.M.</given-names></name><name><surname>Coimbra</surname><given-names>T.L.</given-names></name><name><surname>Silveira</surname><given-names>V.R.</given-names></name><name><surname>Rocco</surname><given-names>I.M.</given-names></name><name><surname>Bisordi</surname><given-names>I.</given-names></name><name><surname>Souza</surname><given-names>R.P.</given-names></name><etal/></person-group><article-title>Yellow fever epizootics in non-human primates, Sao Paulo state, Brazil, 2008-2009</article-title><source>Rev. Inst. Med. Trop. Sao Paulo</source><year>2013</year><volume>55</volume><fpage>45</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1590/S0036-46652013000100008</pub-id><?supplied-pmid 23328725?><pub-id pub-id-type="pmid">23328725</pub-id></element-citation></ref><ref id="B72-vaccines-07-00179"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowman</surname><given-names>L.R.</given-names></name><name><surname>Donegan</surname><given-names>S.</given-names></name><name><surname>McCall</surname><given-names>P.J.</given-names></name></person-group><article-title>Is Dengue Vector Control Deficient in Effectiveness or Evidence?: Systematic Review and Meta-analysis</article-title><source>PLoS Negl. Trop. Dis.</source><year>2016</year><volume>10</volume><elocation-id>e0004551</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0004551</pub-id><pub-id pub-id-type="pmid">26986468</pub-id></element-citation></ref><ref id="B73-vaccines-07-00179"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>A.L.</given-names></name><name><surname>Boelaert</surname><given-names>M.</given-names></name><name><surname>Kleinschmidt</surname><given-names>I.</given-names></name><name><surname>Pinder</surname><given-names>M.</given-names></name><name><surname>Scott</surname><given-names>T.W.</given-names></name><name><surname>Tusting</surname><given-names>L.S.</given-names></name><name><surname>Lindsay</surname><given-names>S.W.</given-names></name></person-group><article-title>Evidence-based vector control? Improving the quality of vector control trials</article-title><source>Trends Parasitol.</source><year>2015</year><volume>31</volume><fpage>380</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2015.04.015</pub-id><pub-id pub-id-type="pmid">25999026</pub-id></element-citation></ref><ref id="B74-vaccines-07-00179"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yakob</surname><given-names>L.</given-names></name><name><surname>Funk</surname><given-names>S.</given-names></name><name><surname>Camacho</surname><given-names>A.</given-names></name><name><surname>Brady</surname><given-names>O.</given-names></name><name><surname>Edmunds</surname><given-names>W.J.</given-names></name></person-group><article-title>Aedes aegypti Control Through Modernized, Integrated Vector Management</article-title><source>PLoS Curr.</source><year>2017</year><volume>9</volume><pub-id pub-id-type="doi">10.1371/currents.outbreaks.45deb8e03a438c4d088afb4fafae8747</pub-id></element-citation></ref><ref id="B75-vaccines-07-00179"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roiz</surname><given-names>D.</given-names></name><name><surname>Wilson</surname><given-names>A.L.</given-names></name><name><surname>Scott</surname><given-names>T.W.</given-names></name><name><surname>Fonseca</surname><given-names>D.M.</given-names></name><name><surname>Jourdain</surname><given-names>F.</given-names></name><name><surname>Muller</surname><given-names>P.</given-names></name><name><surname>Velayudhan</surname><given-names>R.</given-names></name><name><surname>Corbel</surname><given-names>V.</given-names></name></person-group><article-title>Integrated Aedes management for the control of Aedes-borne diseases</article-title><source>PLoS Negl. Trop. Dis.</source><year>2018</year><volume>12</volume><elocation-id>e0006845</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0006845</pub-id><pub-id pub-id-type="pmid">30521524</pub-id></element-citation></ref><ref id="B76-vaccines-07-00179"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staples</surname><given-names>J.E.</given-names></name><name><surname>Bocchini</surname><given-names>J.A.</given-names><suffix>Jr.</suffix></name><name><surname>Rubin</surname><given-names>L.</given-names></name><name><surname>Fischer</surname><given-names>M.</given-names></name></person-group><article-title>Yellow Fever Vaccine Booster Doses: Recommendations of the Advisory Committee on Immunization Practices, 2015</article-title><source>Morb. Mortal. Wkly. Rep.</source><year>2015</year><volume>64</volume><fpage>647</fpage><lpage>650</lpage></element-citation></ref><ref id="B77-vaccines-07-00179"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shearer</surname><given-names>F.M.</given-names></name><name><surname>Longbottom</surname><given-names>J.</given-names></name><name><surname>Browne</surname><given-names>A.J.</given-names></name><name><surname>Pigott</surname><given-names>D.M.</given-names></name><name><surname>Brady</surname><given-names>O.J.</given-names></name><name><surname>Kraemer</surname><given-names>M.U.G.</given-names></name><name><surname>Marinho</surname><given-names>F.</given-names></name><name><surname>Yactayo</surname><given-names>S.</given-names></name><name><surname>de Araujo</surname><given-names>V.E.M.</given-names></name><name><surname>da Nobrega</surname><given-names>A.A.</given-names></name><etal/></person-group><article-title>Existing and potential infection risk zones of yellow fever worldwide: A modelling analysis</article-title><source>Lancet Glob. Health</source><year>2018</year><volume>6</volume><fpage>e270</fpage><lpage>e278</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(18)30024-X</pub-id><pub-id pub-id-type="pmid">29398634</pub-id></element-citation></ref><ref id="B78-vaccines-07-00179"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamlet</surname><given-names>A.</given-names></name><name><surname>Jean</surname><given-names>K.</given-names></name><name><surname>Yactayo</surname><given-names>S.</given-names></name><name><surname>Benzler</surname><given-names>J.</given-names></name><name><surname>Cibrelus</surname><given-names>L.</given-names></name><name><surname>Ferguson</surname><given-names>N.</given-names></name><name><surname>Garske</surname><given-names>T.</given-names></name></person-group><article-title>POLICI: A web application for visualising and extracting yellow fever vaccination coverage in Africa</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><fpage>1384</fpage><lpage>1388</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.01.074</pub-id><pub-id pub-id-type="pmid">30770224</pub-id></element-citation></ref><ref id="B79-vaccines-07-00179"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polonsky</surname><given-names>J.A.</given-names></name><name><surname>Baidjoe</surname><given-names>A.</given-names></name><name><surname>Kamvar</surname><given-names>Z.N.</given-names></name><name><surname>Cori</surname><given-names>A.</given-names></name><name><surname>Durski</surname><given-names>K.</given-names></name><name><surname>Edmunds</surname><given-names>W.J.</given-names></name><name><surname>Eggo</surname><given-names>R.M.</given-names></name><name><surname>Funk</surname><given-names>S.</given-names></name><name><surname>Kaiser</surname><given-names>L.</given-names></name><name><surname>Keating</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Outbreak analytics: A developing data science for informing the response to emerging pathogens</article-title><source>Philos. Trans. R. Soc. B</source><year>2019</year><volume>374</volume><pub-id pub-id-type="doi">10.1098/rstb.2018.0276</pub-id><?supplied-pmid 31104603?><pub-id pub-id-type="pmid">31104603</pub-id></element-citation></ref><ref id="B80-vaccines-07-00179"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraemer</surname><given-names>M.U.G.</given-names></name><name><surname>Cummings</surname><given-names>D.A.T.</given-names></name><name><surname>Funk</surname><given-names>S.</given-names></name><name><surname>Reiner</surname><given-names>R.C.</given-names></name><name><surname>Faria</surname><given-names>N.R.</given-names></name><name><surname>Pybus</surname><given-names>O.G.</given-names></name><name><surname>Cauchemez</surname><given-names>S.</given-names></name></person-group><article-title>Reconstruction and prediction of viral disease epidemics</article-title><source>Epidemiol. Infect.</source><year>2019</year><volume>147</volume><pub-id pub-id-type="doi">10.1017/S0950268818002881</pub-id><?supplied-pmid 30394230?><pub-id pub-id-type="pmid">30394230</pub-id></element-citation></ref><ref id="B81-vaccines-07-00179"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Childs</surname><given-names>M.L.</given-names></name><name><surname>Nova</surname><given-names>N.</given-names></name><name><surname>Colvin</surname><given-names>J.</given-names></name><name><surname>Mordecai</surname><given-names>E.A.</given-names></name></person-group><article-title>Mosquito and primate ecology predict human risk of yellow fever virus spillover in Brazil</article-title><source>Philos. Trans. R. Soc. Lond. B Biol. Sci.</source><year>2019</year><volume>374</volume><fpage>20180335</fpage><pub-id pub-id-type="doi">10.1098/rstb.2018.0335</pub-id><?supplied-pmid 31401964?><pub-id pub-id-type="pmid">31401964</pub-id></element-citation></ref><ref id="B82-vaccines-07-00179"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>H.H.</given-names></name><name><surname>Theiler</surname><given-names>M.</given-names></name></person-group><article-title>The Adaptation of Unmodified Strains of Yellow Fever Virus to Cultivation in Vitro</article-title><source>J. Exp. Med.</source><year>1937</year><volume>65</volume><fpage>801</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1084/jem.65.6.801</pub-id><pub-id pub-id-type="pmid">19870635</pub-id></element-citation></ref><ref id="B83-vaccines-07-00179"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stokes</surname><given-names>A.</given-names></name><name><surname>Bauer</surname><given-names>J.H.</given-names></name><name><surname>Hudson</surname><given-names>X.P.</given-names></name></person-group><article-title>Experimental transmission of yellow fever to laboratory animals</article-title><source>Am. J. Trop. Med.</source><year>1928</year><volume>8</volume><fpage>103</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.1928.s1-8.103</pub-id></element-citation></ref><ref id="B84-vaccines-07-00179"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theiler</surname><given-names>M.</given-names></name><name><surname>Smith</surname><given-names>H.H.</given-names></name></person-group><article-title>The Effect of Prolonged Cultivation in Vitro Upon the Pathogenicity of Yellow Fever Virus</article-title><source>J. Exp. Med.</source><year>1937</year><volume>65</volume><fpage>767</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1084/jem.65.6.767</pub-id><pub-id pub-id-type="pmid">19870633</pub-id></element-citation></ref><ref id="B85-vaccines-07-00179"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferguson</surname><given-names>M.</given-names></name><name><surname>Shin</surname><given-names>J.</given-names></name><name><surname>Knezevic</surname><given-names>I.</given-names></name><name><surname>Minor</surname><given-names>P.</given-names></name><name><surname>Barrett</surname><given-names>A.</given-names></name></person-group><article-title>WHO Working Group on Technical Specifications for Manufacture and Evaluation of Yellow Fever Vaccines, Geneva, Switzerland, 13&#x02013;14 May 2009</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>8236</fpage><lpage>8245</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.10.070</pub-id><pub-id pub-id-type="pmid">21055492</pub-id></element-citation></ref><ref id="B86-vaccines-07-00179"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>A.D.</given-names></name></person-group><article-title>Yellow Fever in Angola and Beyond&#x02014;The Problem of Vaccine Supply and Demand</article-title><source>N. Engl. J. Med.</source><year>2016</year><volume>375</volume><fpage>301</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1056/NEJMp1606997</pub-id><pub-id pub-id-type="pmid">27276108</pub-id></element-citation></ref><ref id="B87-vaccines-07-00179"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shearer</surname><given-names>F.M.</given-names></name><name><surname>Moyes</surname><given-names>C.L.</given-names></name><name><surname>Pigott</surname><given-names>D.M.</given-names></name><name><surname>Brady</surname><given-names>O.J.</given-names></name><name><surname>Marinho</surname><given-names>F.</given-names></name><name><surname>Deshpande</surname><given-names>A.</given-names></name><name><surname>Longbottom</surname><given-names>J.</given-names></name><name><surname>Browne</surname><given-names>A.J.</given-names></name><name><surname>Kraemer</surname><given-names>M.U.G.</given-names></name><name><surname>O&#x02019;Reilly</surname><given-names>K.M.</given-names></name><etal/></person-group><article-title>Global yellow fever vaccination coverage from 1970 to 2016: An adjusted retrospective analysis</article-title><source>Lancet Infect. Dis.</source><year>2017</year><volume>17</volume><fpage>1209</fpage><lpage>1217</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(17)30419-X</pub-id><pub-id pub-id-type="pmid">28822780</pub-id></element-citation></ref><ref id="B88-vaccines-07-00179"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gershman</surname><given-names>M.D.</given-names></name><name><surname>Sotir</surname><given-names>M.J.</given-names></name></person-group><article-title>Update: Temporary Total Depletion of U.S. Licensed Yellow Fever Vaccine for Civilian Travelers Addressed by Investigational New Drug Use of Imported Stamaril Vaccine</article-title><source>Morb. Mortal. Wkly. Rep.</source><year>2017</year><volume>66</volume><fpage>780</fpage><pub-id pub-id-type="doi">10.15585/mmwr.mm6629a4</pub-id></element-citation></ref><ref id="B89-vaccines-07-00179"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J.T.</given-names></name><name><surname>Peak</surname><given-names>C.M.</given-names></name><name><surname>Leung</surname><given-names>G.M.</given-names></name><name><surname>Lipsitch</surname><given-names>M.</given-names></name></person-group><article-title>Fractional dosing of yellow fever vaccine to extend supply: A modelling study</article-title><source>Lancet</source><year>2016</year><volume>388</volume><fpage>2904</fpage><lpage>2911</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)31838-4</pub-id><pub-id pub-id-type="pmid">27837923</pub-id></element-citation></ref><ref id="B90-vaccines-07-00179"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>WHO position on the use of fractional doses&#x02014;June 2017, addendum to vaccines and vaccination against yellow fever WHO: Position paper&#x02014;June 2013</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>5751</fpage><lpage>5752</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.06.087</pub-id><?supplied-pmid 28689653?><pub-id pub-id-type="pmid">28689653</pub-id></element-citation></ref><ref id="B91-vaccines-07-00179"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.H.</given-names></name><name><surname>Hamer</surname><given-names>D.H.</given-names></name></person-group><article-title>Vaccination Challenges in Confronting the Resurgent Threat From Yellow Fever</article-title><source>J. Am. Med Assoc.</source><year>2017</year><volume>318</volume><fpage>1651</fpage><lpage>1652</lpage><pub-id pub-id-type="doi">10.1001/jama.2017.14258</pub-id><?supplied-pmid 28983553?><pub-id pub-id-type="pmid">28983553</pub-id></element-citation></ref><ref id="B92-vaccines-07-00179"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Costa-Rocha</surname><given-names>I.A.</given-names></name><name><surname>Campi-Azevedo</surname><given-names>A.C.</given-names></name><name><surname>Peruhype-Magalhaes</surname><given-names>V.</given-names></name><name><surname>Coelho-Dos-Reis</surname><given-names>J.G.</given-names></name><name><surname>Fradico</surname><given-names>J.R.B.</given-names></name><name><surname>Souza-Lopes</surname><given-names>T.</given-names></name><name><surname>Reis</surname><given-names>L.R.</given-names></name><name><surname>Freire</surname><given-names>L.C.</given-names></name><name><surname>Costa-Pereira</surname><given-names>C.</given-names></name><name><surname>Mambrini</surname><given-names>J.V.M.</given-names></name><etal/></person-group><article-title>Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>1211</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.01211</pub-id><pub-id pub-id-type="pmid">31293563</pub-id></element-citation></ref><ref id="B93-vaccines-07-00179"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casey</surname><given-names>R.M.</given-names></name><name><surname>Harris</surname><given-names>J.B.</given-names></name><name><surname>Ahuka-Mundeke</surname><given-names>S.</given-names></name><name><surname>Dixon</surname><given-names>M.G.</given-names></name><name><surname>Kizito</surname><given-names>G.M.</given-names></name><name><surname>Nsele</surname><given-names>P.M.</given-names></name><name><surname>Umutesi</surname><given-names>G.</given-names></name><name><surname>Laven</surname><given-names>J.</given-names></name><name><surname>Kosoy</surname><given-names>O.</given-names></name><name><surname>Paluku</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever Outbreak&#x02014;Final Report</article-title><source>N. Engl. J. Med.</source><year>2019</year><volume>381</volume><fpage>444</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1710430</pub-id><pub-id pub-id-type="pmid">29443626</pub-id></element-citation></ref><ref id="B94-vaccines-07-00179"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindsey</surname><given-names>N.P.</given-names></name><name><surname>Rabe</surname><given-names>I.B.</given-names></name><name><surname>Miller</surname><given-names>E.R.</given-names></name><name><surname>Fischer</surname><given-names>M.</given-names></name><name><surname>Staples</surname><given-names>J.E.</given-names></name></person-group><article-title>Adverse event reports following yellow fever vaccination, 2007&#x02013;2013</article-title><source>J. Travel Med.</source><year>2016</year><volume>23</volume><pub-id pub-id-type="doi">10.1093/jtm/taw045</pub-id></element-citation></ref><ref id="B95-vaccines-07-00179"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindsey</surname><given-names>N.P.</given-names></name><name><surname>Schroeder</surname><given-names>B.A.</given-names></name><name><surname>Miller</surname><given-names>E.R.</given-names></name><name><surname>Braun</surname><given-names>M.M.</given-names></name><name><surname>Hinckley</surname><given-names>A.F.</given-names></name><name><surname>Marano</surname><given-names>N.</given-names></name><name><surname>Slade</surname><given-names>B.A.</given-names></name><name><surname>Barnett</surname><given-names>E.D.</given-names></name><name><surname>Brunette</surname><given-names>G.W.</given-names></name><name><surname>Horan</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Adverse event reports following yellow fever vaccination</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>6077</fpage><lpage>6082</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.09.009</pub-id><pub-id pub-id-type="pmid">18809449</pub-id></element-citation></ref><ref id="B96-vaccines-07-00179"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monath</surname><given-names>T.P.</given-names></name></person-group><article-title>Review of the risks and benefits of yellow fever vaccination including some new analyses</article-title><source>Expert Rev. Vaccines</source><year>2012</year><volume>11</volume><fpage>427</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1586/erv.12.6</pub-id><pub-id pub-id-type="pmid">22551029</pub-id></element-citation></ref><ref id="B97-vaccines-07-00179"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayes</surname><given-names>E.B.</given-names></name></person-group><article-title>Is it time for a new yellow fever vaccine?</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>8073</fpage><lpage>8076</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.10.015</pub-id><pub-id pub-id-type="pmid">20971115</pub-id></element-citation></ref><ref id="B98-vaccines-07-00179"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amanna</surname><given-names>I.J.</given-names></name><name><surname>Slifka</surname><given-names>M.K.</given-names></name></person-group><article-title>Questions regarding the safety and duration of immunity following live yellow fever vaccination</article-title><source>Expert Rev. Vaccines</source><year>2016</year><volume>15</volume><fpage>1519</fpage><lpage>1533</lpage><pub-id pub-id-type="doi">10.1080/14760584.2016.1198259</pub-id><pub-id pub-id-type="pmid">27267203</pub-id></element-citation></ref><ref id="B99-vaccines-07-00179"><label>99.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Centers for Disease Control and Prevention</collab></person-group><source>Contraindications for Administering Yellow Fever Vaccine</source><publisher-name>Centers for Disease Control and Prevention</publisher-name><publisher-loc>Atlanta, GA, USA</publisher-loc><year>2019</year><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/travel-training/local/HistoryEpidemiologyandVaccination/contraindications-administering-yellow-fever-vaccine.pdf">https://www.cdc.gov/travel-training/local/HistoryEpidemiologyandVaccination/contraindications-administering-yellow-fever-vaccine.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-10-25">(accessed on 25 October 2019)</date-in-citation></element-citation></ref><ref id="B100-vaccines-07-00179"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gershman</surname><given-names>M.D.</given-names></name><name><surname>Staples</surname><given-names>J.E.</given-names></name><name><surname>Bentsi-Enchill</surname><given-names>A.D.</given-names></name><name><surname>Breugelmans</surname><given-names>J.G.</given-names></name><name><surname>Brito</surname><given-names>G.S.</given-names></name><name><surname>Camacho</surname><given-names>L.A.</given-names></name><name><surname>Cottin</surname><given-names>P.</given-names></name><name><surname>Domingo</surname><given-names>C.</given-names></name><name><surname>Durbin</surname><given-names>A.</given-names></name><name><surname>Gascon</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Viscerotropic disease: Case definition and guidelines for collection, analysis, and presentation of immunization safety data</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>5038</fpage><lpage>5058</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.04.067</pub-id><?supplied-pmid 22561144?><pub-id pub-id-type="pmid">22561144</pub-id></element-citation></ref><ref id="B101-vaccines-07-00179"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez</surname><given-names>N.</given-names></name><name><surname>Bucciol</surname><given-names>G.</given-names></name><name><surname>Moens</surname><given-names>L.</given-names></name><name><surname>Le Pen</surname><given-names>J.</given-names></name><name><surname>Shahrooei</surname><given-names>M.</given-names></name><name><surname>Goudouris</surname><given-names>E.</given-names></name><name><surname>Shirkani</surname><given-names>A.</given-names></name><name><surname>Changi-Ashtiani</surname><given-names>M.</given-names></name><name><surname>Rokni-Zadeh</surname><given-names>H.</given-names></name><name><surname>Sayar</surname><given-names>E.H.</given-names></name><etal/></person-group><article-title>Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines</article-title><source>J. Exp. Med.</source><year>2019</year><volume>216</volume><fpage>2057</fpage><lpage>2070</lpage><pub-id pub-id-type="doi">10.1084/jem.20182295</pub-id><?supplied-pmid 31270247?><pub-id pub-id-type="pmid">31270247</pub-id></element-citation></ref><ref id="B102-vaccines-07-00179"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeSilva</surname><given-names>M.</given-names></name><name><surname>Sharma</surname><given-names>A.</given-names></name><name><surname>Staples</surname><given-names>E.</given-names></name><name><surname>Arndt</surname><given-names>B.</given-names></name><name><surname>Shieh</surname><given-names>W.J.</given-names></name><name><surname>Shames</surname><given-names>J.</given-names></name><name><surname>Cieslak</surname><given-names>P.</given-names></name></person-group><article-title>Notes from the field: Fatal yellow fever vaccine-associated viscerotropic disease&#x02014;Oregon, September 2014</article-title><source>Morb. Mortal. Wkly. Rep.</source><year>2015</year><volume>64</volume><fpage>279</fpage><lpage>281</lpage></element-citation></ref><ref id="B103-vaccines-07-00179"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seligman</surname><given-names>S.J.</given-names></name></person-group><article-title>Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD)</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>5769</fpage><lpage>5775</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.08.051</pub-id><pub-id pub-id-type="pmid">25192973</pub-id></element-citation></ref><ref id="B104-vaccines-07-00179"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayes</surname><given-names>E.B.</given-names></name></person-group><article-title>Acute viscerotropic disease following vaccination against yellow fever</article-title><source>Trans. R. Soc. Trop. Med. Hyg</source><year>2007</year><volume>101</volume><fpage>967</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1016/j.trstmh.2007.06.013</pub-id><pub-id pub-id-type="pmid">17669451</pub-id></element-citation></ref><ref id="B105-vaccines-07-00179"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roukens</surname><given-names>A.H.</given-names></name><name><surname>Soonawala</surname><given-names>D.</given-names></name><name><surname>Joosten</surname><given-names>S.A.</given-names></name><name><surname>de Visser</surname><given-names>A.W.</given-names></name><name><surname>Jiang</surname><given-names>X.</given-names></name><name><surname>Dirksen</surname><given-names>K.</given-names></name><name><surname>de Gruijter</surname><given-names>M.</given-names></name><name><surname>van Dissel</surname><given-names>J.T.</given-names></name><name><surname>Bredenbeek</surname><given-names>P.J.</given-names></name><name><surname>Visser</surname><given-names>L.G.</given-names></name></person-group><article-title>Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: A prospective controlled cohort study</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e27753</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0027753</pub-id><pub-id pub-id-type="pmid">22163273</pub-id></element-citation></ref><ref id="B106-vaccines-07-00179"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meier</surname><given-names>K.C.</given-names></name><name><surname>Gardner</surname><given-names>C.L.</given-names></name><name><surname>Khoretonenko</surname><given-names>M.V.</given-names></name><name><surname>Klimstra</surname><given-names>W.B.</given-names></name><name><surname>Ryman</surname><given-names>K.D.</given-names></name></person-group><article-title>A mouse model for studying viscerotropic disease caused by yellow fever virus infection</article-title><source>PLoS Pathog.</source><year>2009</year><volume>5</volume><elocation-id>e1000614</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000614</pub-id><pub-id pub-id-type="pmid">19816561</pub-id></element-citation></ref><ref id="B107-vaccines-07-00179"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erickson</surname><given-names>A.K.</given-names></name><name><surname>Pfeiffer</surname><given-names>J.K.</given-names></name></person-group><article-title>Dynamic viral dissemination in mice infected with yellow fever virus strain 17D</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>12392</fpage><lpage>12397</lpage><pub-id pub-id-type="doi">10.1128/JVI.02149-13</pub-id><pub-id pub-id-type="pmid">24027319</pub-id></element-citation></ref><ref id="B108-vaccines-07-00179"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhiman</surname><given-names>G.</given-names></name><name><surname>Abraham</surname><given-names>R.</given-names></name><name><surname>Griffin</surname><given-names>D.E.</given-names></name></person-group><article-title>Human Schwann cells are susceptible to infection with Zika and yellow fever viruses, but not dengue virus</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><fpage>9951</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-46389-0</pub-id><pub-id pub-id-type="pmid">31289325</pub-id></element-citation></ref><ref id="B109-vaccines-07-00179"><label>109.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Stuart</surname><given-names>G.</given-names></name></person-group><source>Rections Folowing Vaccination against Yellow Fever</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>1956</year></element-citation></ref><ref id="B110-vaccines-07-00179"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartol</surname><given-names>K.D.</given-names></name><name><surname>Aguirre</surname><given-names>J.L.</given-names></name><name><surname>Labruzzo</surname><given-names>S.V.</given-names></name><name><surname>Henriet</surname><given-names>R.P.</given-names></name></person-group><article-title>Transverse myelitis associated with yellow fever vaccination</article-title><source>Bayl. Univ. Med Cent. Proc.</source><year>2019</year><volume>32</volume><fpage>283</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1080/08998280.2019.1573405</pub-id></element-citation></ref><ref id="B111-vaccines-07-00179"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>E.J.</given-names></name><name><surname>Bell</surname><given-names>D.J.</given-names></name><name><surname>Gunson</surname><given-names>R.N.</given-names></name></person-group><article-title>Yellow fever vaccine-associated neurological disease: It is not just the silver generation at risk</article-title><source>BMJ Case Rep.</source><year>2019</year><volume>12</volume><pub-id pub-id-type="doi">10.1136/bcr-2019-229558</pub-id><?supplied-pmid 31088820?><pub-id pub-id-type="pmid">31088820</pub-id></element-citation></ref><ref id="B112-vaccines-07-00179"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMahon</surname><given-names>A.W.</given-names></name><name><surname>Eidex</surname><given-names>R.B.</given-names></name><name><surname>Marfin</surname><given-names>A.A.</given-names></name><name><surname>Russell</surname><given-names>M.</given-names></name><name><surname>Sejvar</surname><given-names>J.J.</given-names></name><name><surname>Markoff</surname><given-names>L.</given-names></name><name><surname>Hayes</surname><given-names>E.B.</given-names></name><name><surname>Chen</surname><given-names>R.T.</given-names></name><name><surname>Ball</surname><given-names>R.</given-names></name><name><surname>Braun</surname><given-names>M.M.</given-names></name><etal/></person-group><article-title>Neurologic disease associated with 17D-204 yellow fever vaccination: A report of 15 cases</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>1727</fpage><lpage>1734</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.11.027</pub-id><?supplied-pmid 17240001?><pub-id pub-id-type="pmid">17240001</pub-id></element-citation></ref><ref id="B113-vaccines-07-00179"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Traiber</surname><given-names>C.</given-names></name><name><surname>Coelho-Amaral</surname><given-names>P.</given-names></name><name><surname>Ritter</surname><given-names>V.R.</given-names></name><name><surname>Winge</surname><given-names>A.</given-names></name></person-group><article-title>Infant meningoencephalitis caused by yellow fever vaccine virus transmitted via breastmilk</article-title><source>J. Pediatr.</source><year>2011</year><volume>87</volume><fpage>269</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.2223/JPED.2067</pub-id><?supplied-pmid 21461453?><pub-id pub-id-type="pmid">21461453</pub-id></element-citation></ref><ref id="B114-vaccines-07-00179"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>S.</given-names></name><name><surname>Twele-Montecinos</surname><given-names>L.</given-names></name><name><surname>MacDonald</surname><given-names>J.</given-names></name><name><surname>Webster</surname><given-names>P.</given-names></name><name><surname>Law</surname><given-names>B.</given-names></name></person-group><article-title>Case report: Probable transmission of vaccine strain of yellow fever virus to an infant via breast milk</article-title><source>CMAJ</source><year>2011</year><volume>183</volume><fpage>E243</fpage><lpage>E245</lpage><pub-id pub-id-type="doi">10.1503/cmaj.100619</pub-id><pub-id pub-id-type="pmid">21324845</pub-id></element-citation></ref><ref id="B115-vaccines-07-00179"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Centers for Disease Control and Prevention</collab></person-group><article-title>Transmission of yellow fever vaccine virus through breast-feeding-Brazil, 2009</article-title><source>Morb. Mortal. Wkly. Rep.</source><year>2010</year><volume>59</volume><fpage>130</fpage><lpage>132</lpage></element-citation></ref><ref id="B116-vaccines-07-00179"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monath</surname><given-names>T.P.</given-names></name><name><surname>Vasconcelos</surname><given-names>P.F.</given-names></name></person-group><article-title>Yellow fever</article-title><source>J. Clin. Virol.</source><year>2015</year><volume>64</volume><fpage>160</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2014.08.030</pub-id><pub-id pub-id-type="pmid">25453327</pub-id></element-citation></ref><ref id="B117-vaccines-07-00179"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gotuzzo</surname><given-names>E.</given-names></name><name><surname>Yactayo</surname><given-names>S.</given-names></name><name><surname>Cordova</surname><given-names>E.</given-names></name></person-group><article-title>Efficacy and duration of immunity after yellow fever vaccination: Systematic review on the need for a booster every 10 years</article-title><source>Am. J. Trop. Med. Hyg.</source><year>2013</year><volume>89</volume><fpage>434</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.13-0264</pub-id><pub-id pub-id-type="pmid">24006295</pub-id></element-citation></ref><ref id="B118-vaccines-07-00179"><label>118.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>Background Paper on Yellow Fever Vaccine</source><comment>SAGE Working Group</comment><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2013</year></element-citation></ref><ref id="B119-vaccines-07-00179"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campi-Azevedo</surname><given-names>A.C.</given-names></name><name><surname>Reis</surname><given-names>L.R.</given-names></name><name><surname>Peruhype-Magalhaes</surname><given-names>V.</given-names></name><name><surname>Coelho-Dos-Reis</surname><given-names>J.G.</given-names></name><name><surname>Antonelli</surname><given-names>L.R.</given-names></name><name><surname>Fonseca</surname><given-names>C.T.</given-names></name><name><surname>Costa-Pereira</surname><given-names>C.</given-names></name><name><surname>Souza-Fagundes</surname><given-names>E.M.</given-names></name><name><surname>da Costa-Rocha</surname><given-names>I.A.</given-names></name><name><surname>Mambrini</surname><given-names>J.V.M.</given-names></name><etal/></person-group><article-title>Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>2192</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.02192</pub-id><pub-id pub-id-type="pmid">31616412</pub-id></element-citation></ref><ref id="B120-vaccines-07-00179"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pato</surname><given-names>T.P.</given-names></name><name><surname>Souza</surname><given-names>M.C.O.</given-names></name><name><surname>Mattos</surname><given-names>D.A.</given-names></name><name><surname>Caride</surname><given-names>E.</given-names></name><name><surname>Ferreira</surname><given-names>D.F.</given-names></name><name><surname>Gaspar</surname><given-names>L.P.</given-names></name><name><surname>Freire</surname><given-names>M.S.</given-names></name><name><surname>Castilho</surname><given-names>L.R.</given-names></name></person-group><article-title>Purification of yellow fever virus produced in Vero cells for inactivated vaccine manufacture</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><fpage>3214</fpage><lpage>3220</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.04.077</pub-id><pub-id pub-id-type="pmid">31047674</pub-id></element-citation></ref><ref id="B121-vaccines-07-00179"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roukens</surname><given-names>A.H.</given-names></name><name><surname>Vossen</surname><given-names>A.C.</given-names></name><name><surname>Bredenbeek</surname><given-names>P.J.</given-names></name><name><surname>van Dissel</surname><given-names>J.T.</given-names></name><name><surname>Visser</surname><given-names>L.G.</given-names></name></person-group><article-title>Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: A randomized controlled non-inferiority trial</article-title><source>PLoS ONE</source><year>2008</year><volume>3</volume><elocation-id>e1993</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0001993</pub-id><pub-id pub-id-type="pmid">18431480</pub-id></element-citation></ref><ref id="B122-vaccines-07-00179"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roukens</surname><given-names>A.H.</given-names></name><name><surname>Gelinck</surname><given-names>L.B.</given-names></name><name><surname>Visser</surname><given-names>L.G.</given-names></name></person-group><article-title>Intradermal vaccination to protect against yellow fever and influenza</article-title><source>Curr. Top. Microbiol. Immunol.</source><year>2012</year><volume>351</volume><fpage>159</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1007/82_2011_124</pub-id><?supplied-pmid 21416266?><pub-id pub-id-type="pmid">21416266</pub-id></element-citation></ref><ref id="B123-vaccines-07-00179"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>A.M.</given-names></name><name><surname>Lam</surname><given-names>L.K.</given-names></name><name><surname>Klimstra</surname><given-names>W.B.</given-names></name><name><surname>Ryman</surname><given-names>K.D.</given-names></name></person-group><article-title>The 17D-204 Vaccine Strain-Induced Protection against Virulent Yellow Fever Virus Is Mediated by Humoral Immunity and CD4+ but not CD8+ T Cells</article-title><source>PLoS Pathog.</source><year>2016</year><volume>12</volume><elocation-id>e1005786</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1005786</pub-id><?supplied-pmid 27463517?><pub-id pub-id-type="pmid">27463517</pub-id></element-citation></ref><ref id="B124-vaccines-07-00179"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perdomo-Celis</surname><given-names>F.</given-names></name><name><surname>Salvato</surname><given-names>M.S.</given-names></name><name><surname>Medina-Moreno</surname><given-names>S.</given-names></name><name><surname>Zapata</surname><given-names>J.C.</given-names></name></person-group><article-title>T-Cell Response to Viral Hemorrhagic Fevers</article-title><source>Vaccines</source><year>2019</year><volume>7</volume><elocation-id>11</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines7010011</pub-id><?supplied-pmid 30678246?><pub-id pub-id-type="pmid">30678246</pub-id></element-citation></ref><ref id="B125-vaccines-07-00179"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souza</surname><given-names>M.C.</given-names></name><name><surname>Freire</surname><given-names>M.S.</given-names></name><name><surname>Schulze</surname><given-names>E.A.</given-names></name><name><surname>Gaspar</surname><given-names>L.P.</given-names></name><name><surname>Castilho</surname><given-names>L.R.</given-names></name></person-group><article-title>Production of yellow fever virus in microcarrier-based Vero cell cultures</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>6420</fpage><lpage>6423</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.06.023</pub-id><pub-id pub-id-type="pmid">19559120</pub-id></element-citation></ref><ref id="B126-vaccines-07-00179"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monath</surname><given-names>T.P.</given-names></name><name><surname>Lee</surname><given-names>C.K.</given-names></name><name><surname>Julander</surname><given-names>J.G.</given-names></name><name><surname>Brown</surname><given-names>A.</given-names></name><name><surname>Beasley</surname><given-names>D.W.</given-names></name><name><surname>Watts</surname><given-names>D.M.</given-names></name><name><surname>Hayman</surname><given-names>E.</given-names></name><name><surname>Guertin</surname><given-names>P.</given-names></name><name><surname>Makowiecki</surname><given-names>J.</given-names></name><name><surname>Crowell</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Inactivated yellow fever 17D vaccine: Development and nonclinical safety, immunogenicity and protective activity</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>3827</fpage><lpage>3840</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.03.023</pub-id><pub-id pub-id-type="pmid">20347059</pub-id></element-citation></ref><ref id="B127-vaccines-07-00179"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaspar</surname><given-names>L.P.</given-names></name><name><surname>Mendes</surname><given-names>Y.S.</given-names></name><name><surname>Yamamura</surname><given-names>A.M.</given-names></name><name><surname>Almeida</surname><given-names>L.F.</given-names></name><name><surname>Caride</surname><given-names>E.</given-names></name><name><surname>Goncalves</surname><given-names>R.B.</given-names></name><name><surname>Silva</surname><given-names>J.L.</given-names></name><name><surname>Oliveira</surname><given-names>A.C.</given-names></name><name><surname>Galler</surname><given-names>R.</given-names></name><name><surname>Freire</surname><given-names>M.S.</given-names></name></person-group><article-title>Pressure-inactivated yellow fever 17DD virus: Implications for vaccine development</article-title><source>J. Virol. Methods</source><year>2008</year><volume>150</volume><fpage>57</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2008.03.002</pub-id><pub-id pub-id-type="pmid">18420285</pub-id></element-citation></ref><ref id="B128-vaccines-07-00179"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>R.C.</given-names></name><name><surname>Silva</surname><given-names>A.N.</given-names></name><name><surname>Souza</surname><given-names>M.C.</given-names></name><name><surname>Silva</surname><given-names>M.V.</given-names></name><name><surname>Neves</surname><given-names>P.P.</given-names></name><name><surname>Silva</surname><given-names>A.A.</given-names></name><name><surname>Matos</surname><given-names>D.D.</given-names></name><name><surname>Herrera</surname><given-names>M.A.</given-names></name><name><surname>Yamamura</surname><given-names>A.M.</given-names></name><name><surname>Freire</surname><given-names>M.S.</given-names></name><etal/></person-group><article-title>An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>4261</fpage><lpage>4268</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.03.077</pub-id><pub-id pub-id-type="pmid">25862300</pub-id></element-citation></ref><ref id="B129-vaccines-07-00179"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beasley</surname><given-names>D.W.</given-names></name><name><surname>Morin</surname><given-names>M.</given-names></name><name><surname>Lamb</surname><given-names>A.R.</given-names></name><name><surname>Hayman</surname><given-names>E.</given-names></name><name><surname>Watts</surname><given-names>D.M.</given-names></name><name><surname>Lee</surname><given-names>C.K.</given-names></name><name><surname>Trent</surname><given-names>D.W.</given-names></name><name><surname>Monath</surname><given-names>T.P.</given-names></name></person-group><article-title>Adaptation of yellow fever virus 17D to Vero cells is associated with mutations in structural and non-structural protein genes</article-title><source>Virus Res.</source><year>2013</year><volume>176</volume><fpage>280</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2013.04.003</pub-id><pub-id pub-id-type="pmid">23602827</pub-id></element-citation></ref><ref id="B130-vaccines-07-00179"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monath</surname><given-names>T.P.</given-names></name><name><surname>Fowler</surname><given-names>E.</given-names></name><name><surname>Johnson</surname><given-names>C.T.</given-names></name><name><surname>Balser</surname><given-names>J.</given-names></name><name><surname>Morin</surname><given-names>M.J.</given-names></name><name><surname>Sisti</surname><given-names>M.</given-names></name><name><surname>Trent</surname><given-names>D.W.</given-names></name></person-group><article-title>An inactivated cell-culture vaccine against yellow fever</article-title><source>N. Engl. J. Med.</source><year>2011</year><volume>364</volume><fpage>1326</fpage><lpage>1333</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1009303</pub-id><pub-id pub-id-type="pmid">21470010</pub-id></element-citation></ref><ref id="B131-vaccines-07-00179"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amanna</surname><given-names>I.J.</given-names></name><name><surname>Raue</surname><given-names>H.P.</given-names></name><name><surname>Slifka</surname><given-names>M.K.</given-names></name></person-group><article-title>Development of a new hydrogen peroxide-based vaccine platform</article-title><source>Nat. Med.</source><year>2012</year><volume>18</volume><fpage>974</fpage><lpage>979</lpage><pub-id pub-id-type="doi">10.1038/nm.2763</pub-id><pub-id pub-id-type="pmid">22635006</pub-id></element-citation></ref><ref id="B132-vaccines-07-00179"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Julander</surname><given-names>J.G.</given-names></name><name><surname>Testori</surname><given-names>M.</given-names></name><name><surname>Cheminay</surname><given-names>C.</given-names></name><name><surname>Volkmann</surname><given-names>A.</given-names></name></person-group><article-title>Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>1756</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.01756</pub-id><?supplied-pmid 30116244?><pub-id pub-id-type="pmid">30116244</pub-id></element-citation></ref><ref id="B133-vaccines-07-00179"><label>133.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>ClinicalTrials.gov</collab></person-group><article-title>A Phase I Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine with and without Montanide ISA-720 Adjuvant in 18&#x02013;45 Year Old Healthy Volunteers</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/study/NCT02743455?type=Intr&#x00026;cond=yellow+fever&#x00026;phase=0&#x00026;fund=0&#x00026;rank=1">https://clinicaltrials.gov/ct2/show/study/NCT02743455?type=Intr&#x00026;cond=yellow+fever&#x00026;phase=0&#x00026;fund=0&#x00026;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-10-25">(accessed on 25 October 2019)</date-in-citation></element-citation></ref></ref-list></back></article>